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ABSTRACT 
The American University in Cairo 
IDENTIFICATION OF T-CELL EPITOPES IN THE HEPATITIS C 
VIRUS GENOTYPE 4 PROTEOME: A STEP TOWARDS EPITOPE-
DRIVEN VACCINE DEVELOPMENT 
BY: Karim Mohamed Ali Abdel-Hady 
Under the Supervision of Prof. Hassan M.E. Azzazy and Dr. Anne S. De Groot 
 
Hepatitis C is an inflammatory infectious disease of the liver caused by the Hepatitis C 
Virus (HCV). It is a global pandemic, chronically inflicting 150 million people 
worldwide, with millions of new infections arising annually. The standard therapy of 
HCV is expensive, associated with severe side effects, and has variable success rates. 
Thus far, no HCV vaccine has been developed, owing to the challenges that faced and 
still face its development. Despite these challenges, several attempts have been taken to 
develop a vaccine, some of which have progressed to phase II clinical trials. Most of 
these attempts, however, have focused on HCV genotypes 1 and 2 as vaccine targets, and 
almost no attention has been given to HCV genotype 4 (HCV-4), the viral genotype most 
prevalent in the Middle East and Central Africa. In an attempt to fill this gap in HCV-4 
vaccine research, this project describes the in silico identification of a group of highly 
conserved and immunogenic T-cell epitopes from the HCV-4 proteome, using the iVAX 
immunoinformatics toolkit (EpiVax Inc., RI, USA), as a first step towards the 
development of an epitope-driven vaccine against the viral genotype. Furthermore, it puts 
forth a fast and inexpensive method for the validation of the results retrospectively using 
the repository of empirical HCV immune epitope data on the Immune Epitope Database 
(IEDB). 90 HLA class I and 14 HLA class II epitopes were identified. From those, 20 
HLA class I epitopes were found to be previously uncharacterized, while the in silico 
HLA binding predictions for 27 others (class I and class II) have been retrospectively 
validated. The retrospective validation results for 4 of the identified HLA class II 
epitopes were confirmed by a pilot HLA class II binding assay. Furthermore, an 
investigation of the conservancy of a selected set of the identified epitopes in newly re-
sequenced HCV strains from the Egyptian population was performed. The identified and 
retrospectively validated set of epitopes constitutes a good target for further 
immunogenicity testing and epitope-driven vaccine development against HCV-4.  
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1. INTRODUCTION 
 
 Hepatitis C is an infectious inflammatory liver disease caused by the Hepatitis C 
virus (HCV); a blood-borne virus transmitted mainly through the percutaneous route 
from an infected to a healthy individual. According to the World Health Organization 
(WHO), approximately 150 million people suffer from chronic HCV infection 
worldwide, with 3-4 million newly infected each year. Around 350,000 patients die each 
year as a result of HCV-related diseases [1]. There are six major genotypes of the virus  
whose distribution and prevalence varies widely between different regions and countries 
[2]. Global infection rates peak in Egypt, where 22% of the population is chronically 
infected, and an estimate of 500,000 get newly infected each year [1,3]. Over 90% of the 
Egyptian patients are infected with HCV genotype 4 (HCV-4), the most prevalent 
genotype in the Middle East and Central and Western Africa [4-6]. The high prevalence 
of HCV in Egypt has been attributed to the use of contaminated needles in an 
antischistosomal therapy campaign that took place in the 1950s [4-7]; and currently, the 
main route of transmission is through clinical procedures in which improperly sterilized 
instruments are utilized [4,6].  
 Apart from the percutaneous route of transmission, HCV transmission can also 
occur through sexual and perinatal exposures; these routs of transmission, however, are 
much less efficient and are not major contributors to new infections [8]. Following the 
onset of infection, the disease starts with an acute phase that lasts for about 6 months. 
During that phase, 15-30% of the patients are able to clear the virus spontaneously; 
however in 70-85% of the patients the virus manages to evade the host’s immune system 
and persist, leading to the progression of the disease to a chronic phase. The chronic 
phase can last for decades, eventually culminating in liver cirrhosis and/or hepatocellular 
carcinoma for 5-20% of the chronically infected patients and death for 1-5% of the 
patients [1,9,10]. 
 HCV is an enveloped RNA virus belonging to the Hepacivirus genus of the 
family Flaviviridae. Its genome consists of a single sense RNA strand of an approximate 
size of 9600 bases; harboring a single open reading frame (ORF) that is flanked by 5’ and 
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3’ untranslated regions (UTR). The ORF (also known as the polyprotein gene) is 
translated into a precursor polyprotein molecule approximately 3000 amino acids in size. 
This molecule is processed during and after its synthesis via viral and host cellular 
machinery into 10 viral proteins, divided into 3 structural and 7 non-structural 
(functional) proteins (Table 1) [11]. HCV replicates via a viral RNA-dependant-RNA 
polymerase known as Non-Structural protein 5B (NS5B). The enzyme lacks the proof-
reading capability normally present in DNA polymerases, causing the virus to experience 
a very high mutation rate upon replication of approximately 0.0014 to 0.0019 mutations 
per nucleotide per year [11,6]. This high rate of mutation is one of the main mechanisms 
by which the virus manages to evade the host’s adaptive immune system; furthermore, it 
results in the diversification of the virus into a wide array of genetic variants. These 
variants are classified based on the extent of genetic variation into genotypes, varying by 
30-33% of the genome, subtypes, varying by 20-25% of the genome, and quasi-species 
within each patient that may vary from a single point mutation up to 10% or more of the 
genome [2,11]. HCV primarily infects and replicates in liver hepatocytes of human and 
chimpanzee hosts only [12]. Reports also indicate that it is able to infect some peripheral 
blood mononuclear cells such as B-cells and dendritic cells (DCs); however it does not 
replicate within those cells [13]. 
  After the virus infects the liver hepatocytes and commences replication, the 
host’s innate immune system in response attempts to protect the healthy liver hepatocytes 
from infection and kill the infected ones by the actions of Interferons (IFNs) and Natural 
Killer (NK) cells. The adaptive immune response that is later initiated involves 
neutralizing antibodies that may block viral entry into healthy hepatocytes, and the killing 
of the infected hepatocytes by the action of the CD8
+
 cytotoxic T-cells [13-15]. Although 
in 15-30% of the patients the immune system manages to spontaneously clear the virus, 
in the majority of the patients the virus manages to evade the  immune system by several 
mechanisms; leading to the persistence of infection. Chief amongst those mechanisms is 
the highly mutable nature of the virus, which allows for the production of escape variants 
that evade recognition by the cells of the adaptive immune system. Other mechanisms 
include inhibition of type I IFN production, induction of T-cell exhaustion, and induction 
regulatory T-cell action [13,14]. The outcome of HCV infection (spontaneous clearance 
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or persistent infection) is believed to be determined by the strength and nature of the 
immune response during the acute phase of the infection. A strong base of evidence 
demonstrates that a strong, multi-specific and sustained T-cell response to the virus is 
associated with viral clearance. On the other hand, a weak, narrow, and short-lasting T-
cell response is associated with viral persistence. The role of neutralizing antibodies in 
HCV clearance is debatable, while studies show an association between a rapidly-induced 
production of high titers of cross-neutralizing antibodies and spontaneous HCV 
clearance; others have shown that viral clearance is possible in the absence of anti-HCV 
neutralizing antibodies [13,15]. 
 The standard treatment regimen for HCV infection is a combination therapy of 
pegylated IFN alpha and ribavirin. The aim of treatment is to achieve a sustained 
virological response (SVR); defined as the absence of HCV RNA from the patient’s 
blood 24 weeks after the cessation of treatment. This treatment, however, is costly, 
causes severe side effects, and does not guarantee the elimination of infection [10]. 
Recently, with the advent of protease inhibitor direct-acting antiviral drugs (e.g.Telaprivir 
and Boceprivir), the optimum treatment regimen for HCV genotype 1 infection has been 
altered to include a protease inhibitor in a triple therapy with pegylated IFN alpha and 
ribavirin. This new regimen increases the chances of achieving SVR for genotype 1 
infected patients; however it is still expensive, has associated side effects (e.g. dysgeusia, 
severe fatigue, debilitating depression, and hemolysis), and is less effective for treating 
infections with other HCV genotypes such as genotype 4 [16]. The high costs, significant 
side effects, and uncertainty in achieving SVR associated with HCV therapy warrant 
support for the development of an HCV vaccine, a goal that so far has not been achieved 
[17].  
 On top of the persisting challenge of overcoming the various mechanisms by 
which the virus evades the immune system, HCV vaccine development was hampered by 
other technical obstacles. Due to the fastidious nature of the virus, HCV could not be 
produced in tissue culture systems nor was there a readily available animal model of 
infection for it. The gap created by the lack of cell culture systems was filled by the 
development of HCV pseudo type particles (HCVpp) in 2003, and then in 2005 the first 
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tissue culture system of infection was developed [18]. This allowed for the identification 
of the receptors used by the virus for cell entry; which allowed for the production of 
humanized mouse models expressing those receptors. These models are still early in 
development; however their availability could accelerate preclinical vaccine testing 
[17,19]. In spite of those challenges, several vaccine studies have been conducted on 
animal models in the past decade yielding promising results; a small number of which 
have actually progressed to human phase II clinical trials.   
 As aforementioned, HCV-4 is highly prevalent in the Middle East and Central and 
Western Africa and is increasingly spreading to countries in Southern and Western 
Europe and to North America with increasing immigration and travel [20]. In Egypt, 
more than 90% of HCV patients are infected with HCV-4; more than 500,000 new 
infections are estimated to occur in Egypt annually [3,5,7]. Despite the direness of the 
situation, very little attention has been given to the development of therapies and vaccines 
for HCV-4. According to a meta-analysis study performed on all the existing HCV 
epitope data on the Immune Epitope Database (IEDB) (a repository of immune epitope 
data manually curated from reported peer reviewed literature, patents, and direct 
submissions from companies and institutions [21]), only 13 epitopes for HCV genotypes 
4, 5, and 6 combined were reported out of 3444 unique reported HCV epitopes that tested 
positive in T-cell and B-cell assays [22]. In an attempt to fill this wide gap in HCV-4 
immune epitope research, and to address the un-tackled subject of HCV-4 vaccine design, 
this project aims to identify, in silico, a set of highly immunogenic and conserved T-cell 
epitopes from within the HCV-4 proteome as targets for an epitope-driven vaccine for 
HCV-4. The epitopes were identified using the validated immunoinformatics iVAX 
toolkit (EpiVax Inc., RI, USA), a suite of immunoinformatics tools that can be used for 
the in silico design of epitope-driven vaccines derived from protein sequences of interest 
[23]. This project also describes a fast and inexpensive method for the retrospective 
validation of the in silico results using the repository of HCV immune epitope data on the 
IEDB, which can accelerate and cut-down the expenses of the development of the 
vaccine.    
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2. LITERATURE REVIEW 
 
2.1 The Life Cycle of HCV 
 The HCV life cycle begins with the entry of the virus into the liver hepatocytes. In 
the blood, HCV circulates in both free and bound forms; where it can be associated with 
low density lipoproteins (LDL), very low density lipoproteins (VLDL), and 
immunoglobulins [12,24,25]. Once the virus reaches the liver, its entry into the 
hepatocytes is mediated by the attachment of the membrane-bound viral E1-E2 
heterodimer (formed by the dimerization of the HCV structural proteins E1 and E2) to 
hepatocyte cell-surface molecules and receptors; these include CD81, a tetraspanin 
protein expressed on the surface of several cell types, and Scavenger Receptor class B 
type I (SR-BI), a glycoprotein whose natural ligand is high density lipoproteins (HDL). 
Also among those molecules and receptors are the Low Density Lipoprotein receptor 
(LDLR), the tight junction protein Claudin-1 (CLDN-1), glycosaminoglycans (GAG), 
and others. Although further investigation needs to be carried out, studies show that LDL 
receptors together with glycosaminoglycans may act as the primary collectors of HCV 
particles from the blood stream for further targeting to other HCV receptors such as 
CD81. Studies show that CD81 and SR-BI are both necessary but not sufficient for viral 
entry [12,25]. The tight junction protein CLDN-1 was found to be an essential co-
receptor acting at a later stage of the entry process after the virus has interacted with CD-
81. However, like CD81 and SR-BI, it was found insufficient (when co-expressed with 
CD81 and SR-BI) for mediating viral entry [12]; meaning that there are other molecules 
required for the completion of the process.  Following attachment, HCV enters the cell 
via Clathrin-dependent endocytosis. The low pH-environment inside the endosome 
induces the fusion between the viral and endosomal membranes; which is followed by the 
release of the viral nucleocapsid into the cytoplasm [12,25]. Figure 1 schematically 
represents the viral entry step of the HCV life cycle as it is currently understood.  
 After the release of the nucleocapsid into the cytoplasm, the single sense genomic 
RNA strand of HCV is released, and serves as the messenger RNA for the synthesis of 
the viral precursor polyprotein molecule. The translation of the RNA strand is controlled 
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by an Internal Ribosomal Entry Site (IRES), spanning domains II, III, and IV of the 
5’UTR (Figure 2) and the first 24-40 nucleotides of the region coding for the Core 
structural protein. The IRES mediates the initiation of cap-independent translation of the 
polyprotein gene. [12,25]. After the synthesis of the polyprotein molecule is initiated, the 
molecule is directed to the Endoplasmic Reticulum (ER) mediated by an internal signal 
peptide located between the amino acid sequences of the Core and E1 structural proteins; 
this sequence is responsible for mediating the translocation of the ectodomain of the E1 
protein into the ER lumen. At the ER, the polyprotein molecule is processed via host and 
viral enzymes during and after its synthesis into the structural and non-structural proteins 
of HCV. First, the three structural proteins (Core, E1, and E2) and the non-structural 
protein p7 are processed via host ER signal peptidases. The remaining 6 non-structural 
proteins, namely NS2, NS3, NS4A, NS4B, NS5A, and NS5B, are processed via the cis-
acting viral auto-protease NS2-3, and the cis and trans acting NS3-NS4A protease. First, 
the NS2-3 cis-acting auto-protease cleaves the bond between the NS2 and NS3 
polypeptides in the polyprotein chain [12,26]. Then, the NS3 protease with the NS4A 
protein as its co-factor catalyzes cis-cleavage of the NS3/NS4A junction and the trans-
cleavage of the NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B junctions. The processed 
structural and non-structural proteins become associated with the ER membrane [12,25]. 
Figure 2 represents schematically the relative positions of the amino acid sequences of 
the HCV structural and non-structural proteins in the precursor polyprotein sequence, and 
figure 3 schematically represents the 3D structures of the proteins and their associations 
with the ER membrane. 
 Similar to all positive-strand RNA viruses, HCV RNA replication takes place at a 
membrane-associated replication complex composed of replicating RNA, viral proteins, 
and rearranged cellular membranes. The site of HCV RNA replication in the cell is called 
the membranous web; the name given to a specific alteration of the ER whose formation 
is induced by the NS4B viral protein alone. At the membranous web, HCV RNA 
replication is catalyzed by the RNA-dependant RNA polymerase NS5B in a two-step, 
semiconservative, and asymmetric process. In the first step, the positive RNA strand 
serves as a template for the synthesis of an intermediate negative RNA strand. The 
negative strand is then used as a template in the second step for the synthesis of several 
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positive RNA strands; which will later be used for precursor polyprotein synthesis, the 
synthesis of new negative RNA strand intermediates, and for packaging into new virions 
for release from the cell. Both steps of the replication process are catalyzed by NS5B. 
The replication process is modulated by the fluidity of the membranous web which is 
dictated by the degree of saturation of its fatty acid component molecules; where the 
abundance of cholesterol and saturated fatty acids stimulates viral replication and that of 
poly-unsaturated fatty acids inhibits it [12, 25,26].  
 Following viral RNA replication and protein synthesis, the newly synthesized 
positive RNA strands are packaged into new viral particles which are later released from 
the cell. According to available evidence, this packaging process is most likely initiated 
by the interaction of the newly synthesized positive RNA strands with the Core viral 
proteins, which in themselves are capable of self-assembly in order to form the 
nucleocapsid. Virions are then presumably formed by budding into the ER lumen or that 
of an ER-derived compartment; where they are then released from the cell via the 
constitutive secretory pathway [12, 25,26].       
 
2.2 Immunity to HCV  
2.2.1 Effector Mechanisms of the Host Immune Response: 
2.2.1.1 Innate Immunity - Interferons 
 Immediately after HCV infects the liver hepatocytes, the host’s innate immune 
system attempts to combat the infection mainly via the actions of IFNs and NK cells. 
Interferons are a family of secreted cytokines that act in autocrine and paracrine manners 
to stimulate intracellular networks that modulate mechanisms of resistance to viral 
infections, enhance and shape innate and adaptive immune responses, and regulate the 
survival and death of normal and cancerous cells [27]. They are categorized based on 
their cell-surface receptors into three types: type I, type II, and type III. Despite their 
structural and genetic differences, type I and III Interferons share identical induction 
mechanisms, signal transduction pathways, and biological actions; where they both 
induce antiviral activity in their target cells [28]. Type I IFNs are structurally subdivided 
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into IFN-β and several subtypes of IFN-α; they can be expressed in most body cell types, 
and their receptor is similarly widely expressed. Type III IFNs, also known as λ 
interferons, are divided into 3 subtypes namely IFN-λ1, IFN-λ2, and IFN-λ3, which are 
otherwise known as interleukin (IL)-29, IL-28A, and IL-28B respectively; they are 
expressed in several –but not all- cell types. In contrast to type I and type III Interferons, 
the type II interferon, comprised in a single molecule denoted IFN-γ, is expressed only in 
NK cells and activated T-cells, and possesses mainly immunomodulatory actions [29,30]. 
IFN-γ will be discussed in more detail later in this section within the context of NK cell 
and T-cell response mechanisms. 
 The production of type I interferons is most potently stimulated by viral 
infections; specifically by the double-stranded RNA intermediates produced during the 
replication of viruses such as HCV [29,31]. After their production, type I interferons 
induce antiviral responses in their target cells by binding to a heterodimeric cell-surface 
receptor called the Interferon-α/β receptor (IFNAR), which is composed of two subunits, 
namely IFNAR1 and IFNAR2. The binding of the interferons to the receptor causes its 
subunits to dimerize, activating a Janus Kinase-Signal Transducer and Activator of 
Transcription (JAK/STAT) signal transduction pathway. The activation of the pathway 
culminates in the activation of transcription of a set of genes, known as the Interferon 
Stimulated Genes (ISG), whose protein products act by inhibiting viral replication in the 
cell. This protects paracrine-induced uninfected cells from infection, and limits the spread 
of the virus from the autocrine-induced infected cells [29,31]. In addition to inhibiting 
viral replication, type I IFNs also promote adaptive cell-mediated immunity against 
intracellular microbe infections by increasing the expression of class I Major 
Histocompatibility Complex (MHC) molecules on the surface of the infected cells. They 
also stimulate the development of CD4
+
 TH1 helper T-cells, and enhance the effector 
functions of NK cells as will be explained later [31].  
Similar to type I IFNs, the production of type III IFNs is also stimulated by viral 
infections. Studies show that both types of IFNs are co-produced upon induction with all 
the inducers that were investigated; suggesting that they are both regulated by the same 
mechanism [28].  Upon binding to their receptor, type III IFNs also activate a JAK/STAT 
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signaling pathway that culminates in the activation of transcription of a set of ISGs 
similar to those activated by type I IFNs; thereby also inhibiting viral replication in 
paracrine and autocrine manners. However, the heterodimeric cell-surface receptor to 
which type III IFNs bind is different, where it is composed of two polypeptide chains 
called IFNLR1 and IL10R2. This receptor is not expressed as broadly as the IFNAR 
receptor on different body cells, however it is expressed in liver hepatocytes [28,29]. 
Studies show that ISGs are generally highly expressed in the livers of HCV-
infected patients [29,30]. Available cell culture studies indicate that HCV pathogen 
associated molecular patterns (PAMPs) responsible for the induction of IFN production, 
which include double-stranded RNA (dsRNA) and viral proteins, are identified by the 
PAMP receptors Retinoic acid-inducible gene I (RIG-I) and the Toll-like receptor 3 
(TLR3); the PAMP receptors TLR2 and TLR7 may also be implicated in HCV detection 
[30]. RIG-I is a cytoplasmic RNA helicase that senses non-self, short dsRNA or ssRNA 
with a free 5’-triphosphate moiety. Toll-like receptors, in general, are membrane-bound, 
mainly endosomal receptors; TLR3 senses dsRNA and viral DNA, TLR2 senses certain 
viral proteins, and TLR7 (mainly expressed in plasmacytoid dendritic cells) senses 
ssRNA. Following HCV detection, these receptors trigger signal transduction pathways 
that induce the expression of type I and III IFNs, which are then secreted to induce the 
expression of ISGs in paracrine and autocrine manners. An example of the ISGs 
expressed in HCV infection is the IFN-stimulated gene 20-kDa protein (ISG20), whose 
protein product is a 3′–5′ exonuclease that suppresses viral replication by targeting 
ssRNA. Another example is the 2’–5’ oligoadenylate synthetase (OAS) enzyme gene, 
whose protein product catalyzes the synthesis of 2’-5’-oligoAdenylic acid, which in turn 
activates a latent endoribonuclease called RNase-L. RNase-L catalyzes the degradation of 
viral ssRNA as well as cellular mRNA and rRNA thereby globally inhibiting protein 
synthesis in the cell and triggering its apoptosis [29,30]. The production of type I and III 
IFNs triggered by HCV is depicted in detail in figure 4. 
2.2.1.2 Innate Immunity – Natural Killer Cells            
 In addition to the antiviral actions of IFNs, NK cells combat HCV infection by 
triggering the apoptosis of infected hepatocytes, thereby preventing the production and 
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spread of new HCV virions to healthy hepatocytes. NK cells are a subset of lymphocytes 
belonging to the T-cell lineage that recognize and kill pathogen-infected cells, cancer 
cells, and cells not expressing self MHC class I molecules, without the need for prior 
sensitization like that required by the T and B cells of the adaptive immune system 
[31,32]. Their activation is regulated by a balance between signals produced from 
activating and inhibitory receptors expressed on their surface. The inhibitory receptors 
bind to self-MHC class I molecules normally expressed in all body cells independent of 
the T-cell epitope that these molecules are presenting in their binding clefts. The 
activating receptors bind to pathogen-derived molecules (proteins and carbohydrates) or 
non-classical MHC molecules that are expressed/upregulated on the surface of infected, 
cancerous, or otherwise stressed body cells. Usually if the inhibitory receptors are 
engaged, the NK cell is not activated due to the dominance of the inhibitory signal. If 
however the inhibitory receptors are not engaged due to the absence of enough normal 
self-MHC I molecules on the surface of the target cell, and at the same time the activating 
receptors are engaged to their target ligands, the NK cell then becomes activated [31,32]. 
It is important to note, however, that if several activatory signals are generated at once, 
they can collectively overwhelm the inhibitory signal and activate the cell. Furthermore, 
in some cases, the engagement of even one activatory receptor may be enough to override 
the inhibitory signal and activate the cell [32].  
 Following activation, NK cells induce apoptosis in their target cells. One way by 
which that happens is via enzymes called Granzymes, which enter the target cells through 
pores in their membrane created by a protein called Perforin. Both Perforins and 
Granzymes are stored in granules in the cytoplasm of NK cells, and are released upon the 
cell’s activation. In addition, activated NK cells secrete IFN-γ [31,32]. IFN-γ performs its 
biological actions via binding to a dimeric receptor that is ubiquitously expressed on all 
nucleated cells called the IFN-γ receptor (IFNGR) [27]. Upon binding, IFN-γ triggers a 
JAK/STAT signaling pathway that culminates in the expression of a set of ISGs that are 
overlapping with –but not identical to- the ones induced by type I and III IFNs. In innate 
immunity, similar to type I and III IFNs, IFN-γ possesses direct antiviral activity, where 
it induces the expression of ISGs that inhibit viral replication in its target cells (e.g. 2’–5’ 
oligoadenylate synthetase (OAS) and Protein Kinase R (PKR)). It also serves as a 
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modulator, where it activates macrophages to kill phagocytosed microbes and stimulates 
the cytotoxic activity of NK cells [33]. In addition to its functions in innate immunity, 
IFN-γ also enhances MHC-associated antigen presentation and recognition during the 
cellular adaptive immune response via stimulating the expression of both classes of MHC 
molecules, co-stimulatory molecules on Antigen Presenting Cells (APCs), and 
intracellular proteins implicated in antigen processing [31-33].   
 In acute HCV infection, studies show that NK cells in peripheral blood increase in 
number and become activated; up-regulating the expression of the activatory receptor 
NKG2D, and down-regulating the expression of inhibitory receptor NKG2A. 
Furthermore, the levels of IFN-γ produced from the NK cells and their cytotoxicity was 
shown to be higher than their counterparts in healthy controls [34]. In the chronic phase 
of the infection, generally, the number and function of NK cells are down-regulated. The 
decrease in NK cell number could be attributed to the decrease/lack of IL-15 produced by 
DCs, the interleukin that is essential for NK cell development and functionality. 
However, it could also be due to the compartmentalization of NK cells away from the 
peripheral blood stream (the site which early studies concerning the subject have 
concentrated on in their analysis). The down-regulation in NK cell function is reflected in 
the decrease in their IFN-γ producing activity and their ability to activate DCs [34,35]. 
Furthermore, NK cells exhibit an increase in IL-10 and TGF-β production; producing an 
immunosuppressive environment that encourages viral persistence [33]. Despite this 
down-regulation in number and cytokine-secreting function, the natural cytotoxic 
functionality of NK cells appears to be intact or increased. This could be explained by the 
fact that there are activatory receptors that are up-regulated on their surface during the 
chronic phase of the infection (e.g. NKp30, NKp44 and NKp46) [34].  
 
2.2.1.3 Innate Immunity – Other Mechanisms                  
 In addition to the actions of IFNs and NK cells, the production of other 
inflammatory cytokines and chemokines is also induced in the HCV-infected liver; which 
are also important mediators bridging the innate and adaptive immune responses, and are 
critical for T-cell homing to the infected liver. Examples of chemokines produced in the 
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liver during HCV infection are the C-C chemokine receptor type 5 (CCR5) ligands: 
Chemokine (C-C motif) ligand 3 (CCL3) and CCL5, and the Chemokine (C-X-C motif) 
receptor 3 (CXCR3) ligands: Interferon gamma-induced protein 10 (IP-10) and 
Chemokine (C-X-C motif) ligand 9 (CXCL9). Studies have shown that there is a 
correlation between the levels of some of those chemokines in the blood of HCV patients 
and the outcome of infection or the severity of liver inflammation [29].     
 The innate immune response to HCV buys time for the development of the 
adaptive immune response to the virus, in addition to being an important factor in 
shaping the later [29]. Unlike the innate immune response, triggering the cells of adaptive 
immune system, the B and T lymphocytes, requires the specific recognition of viral 
antigens. Adaptive immunity is divided into humoral immunity, and cell mediated 
immunity (CMI). Humoral immunity targets extracellular pathogens via antibodies, the 
antigen receptors and effector molecules of B-cells, whereas CMI targets intracellular 
pathogens via the Cytotoxic actions of CD8
+
 T-lymphocytes [36]. 
 
2.2.1.4 Adaptive Immunity – Cell Mediated Response                  
 CMI is the effector response of T-lymphocytes against microbes that infect non-
phagocytic cells and those that survive within phagocytes of phagocytic cells. The best 
defined functional populations of T-lymphocytes involved in the CMI response are the 
helper CD4
+
 T-cells, which play an essential role in stimulating and coordinating the 
adaptive immune response (both humoral and cellular), and the cytotoxic CD8
+
 T-
lymphocytes (CTL), whose role is to kill microbe-infected cells thus inhibiting the spread 
of the infection to un-infected cells [37].  The key to CD4
+
 and CD8
+
 T-lymphocyte 
activation is their recognition of microbial antigens in association with Major 
Histocompatibility Molecules via their antigen receptor, namely the T-cell receptor 
(TCR). Major histocompatibility molecules are specialized proteins encoded by genes in 
the Major Histocompatibility Complex (MHC) locus found on the chromosomes of all 
vertebrates, whose role is to display peptide fragments (epitopes) of digested protein 
antigens on the surface of body cells for recognition by T-lymphocytes. Class I MHC 
molecules present epitopes for recognition by CD8
+
 T-cells, and are expressed on almost 
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all nucleated body cells, while class II MHC molecules present epitopes for recognition 
by CD4
+
 T-cells, and are only present on the surface of antigen presenting cells (APCs) 
such as DCs, mononuclear phagocytes, and B-lymphocytes [36].  
 The only professional APCs that are capable of activating naïve T-cells and 
initiating a primary CMI response are DCs, since they are the only APCs that possess the 
co-stimulatory capacity required to activate those cells [38,39]. The two main types of 
DCs isolated from peripheral blood are myeloid/conventional dendritic cells (mDC), 
which originate from myeloid precursor cells, and plasmacytoid dendritic cells (pDC), 
which originate from lymphoid precursor cells. mDCs and pDCs differ in their 
capabilities of antigen presentation, expression of co-stimulatory molecules, and cytokine 
production.  mDC are much more efficient than pDC at antigen capture, processing, and 
presentation. In the periphery, immature DCs (iDCs) are efficiently capable of capturing 
exogenous antigens via the cell-internalization processes of receptor-mediated 
endocytosis, macropinocytosis, and phagocytosis [38,39]. In the case of HCV, immature 
DCs capture HCV antigens via phagocytosis of apoptotic infected hepatocytes, 
endocytosis of HCV-immune complexes, and/or macropinocytosis of free virions [40]. 
Following antigen capture, DCs begin their maturation process triggered by microbial 
products and inflammatory cytokines, and immigrate towards the secondary lymphoid 
organs for the activation of antigen-specific naïve T helper and cytotoxic cells.  DCs are 
capable of presenting both MHC class II and class I antigenic epitopes via the exogenous 
antigen processing pathway and cross-presentation respectively [38]. Figure 5 
schematically represents the maturation process of iDCs into mDCs following HCV 
capture, and the subsequent activation of T lymphocytes.  
 In chronic HCV infection, studies show that the numbers of DCs (both pDC and 
mDC) in peripheral blood decrease and significantly increase in the liver; with the ratio 
of mDCs to pDCs higher than that of peripheral blood [39]. Several studies also pointed 
out that despite their distribution during chronic infection, DCs are functionally impaired. 
mDCs have been reported to exhibit impaired maturation, decreased IL-12 production, 
increased IL-10 production, lower ability to stimulate allogenic CD4
+
 T-cells, and higher 
ability to stimulate T-regulator (Treg) cells; thereby, like NK cells, they produce an 
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immunosuppressive environment that encourages viral persistence [39,41]. However, 
other studies produced conflicting evidence showing that DCs in chronic HCV infection 
are not functionally impaired. This contradiction in  results is due to several factors such 
as the limited number of study subjects, differences in host-related factors (e.g. age, 
gender), source tissue of the analyzed DCs, and others; confirmation of either claim 
requires further investigations to be carried out [13,39].   
 Upon reaching the peripheral lymphoid organs, mature DCs expressing the B7 co-
stimulatory molecules present the captured and processed HCV antigens to naïve CD8
+
 
and CD4
+
 T-cells on MHC class I and class II molecules respectively. The recognition of 
those antigens, in addition to co-stimulation by the B7 molecules and stimulation by 
activator cytokines produced by the DCs, lead to the activation of circulating antigen-
specific T-cells. Consequently, the activated T-cells proliferate and differentiate into 
effector and memory cell subsets [42]. Activated CD4
+
 T-helper cells differentiate into 
the IFN-γ secreting TH1 effector subset, induced by the cytokines IL-12 and IFN- γ found 
in the immediate cytokine milieu. Activated CD8
+
 T-cytotoxic cells differentiate into 
CTL effector cells which harbor membrane-bound cytoplasmic granules carrying proteins 
required for killing infected cells, including perforins and granzymes, and are able to 
produce certain cytokines including IFN- γ. It is important to note that in addition to the 
activator signals provided by the mature DCs, CD8
+
 T-cells also require stimulation by 
cytokines from TH1 helper cells to successfully differentiate into CTL effector cells 
[31,42]. Following differentiation, part of the effector and memory T-cells migrate to the 
liver, where they are preferentially retained. In the liver, CTLs that recognize their 
specific antigen in association with MHC class I molecules on the surface of infected 
hepatocytes become activated and kill the infected cells by inducing apoptosis. 
Furthermore, CTLs secrete IFN-γ similar to the effector TH1 cells, which apart from 
“helping” the differentiation of CD8+ T-cells into CTLs, stimulates the production of 
opsonizing IgG antibodies from B-cells and the microbicidal activity of phagocytes [31].  
 The evolution of the T-cell response in HCV infected patients can be divided into 
three phases in correlation with the progression of liver inflammation; namely the pre-
acute, acute, and post-acute phases. The pre-acute phase corresponds to the first few 
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weeks following the onset of primary infection where the virus titers rise to very high 
levels and T-cell responses are still undetectable [43]. The acute phase starts 4-12 weeks 
after primary infection onset when HCV-specific CD4
+
 and CD8
+
 T-cells become 
detectable in blood. Concurrent with the rise in effector HCV-specific T-cell titers, HCV 
RNA levels start to fall, often becoming transiently undetectable, and a rise in liver 
enzyme titers may be experienced characterizing the development of acute hepatitis. 
Early in the acute phase, when the viral load is still relatively high, activated HCV-
specific CD8
+
 T-cells demonstrate a unique behavior where they do not secrete IFN-γ and 
are defective in their cyototoxic activity despite their expression of activation markers. 
This phenotype has been described by some investigators as a “stunned” phenotype, 
where the CD8
+
 T-cells act as if they were anergic, and is considered a hallmark of acute 
HCV infection regardless of its outcome. In patients who resolve the infection, HCV-
specific CD8
+
 T-cell functionality is later restored concurrent with a significant drop in 
HCV viral titers [43,44]. 
 The T-cell response to HCV is known to peak on average 6-12 months following 
infection onset; and it is the nature of that response in the acute phase which determines 
the subsequent infection outcome, or to say the characteristics of the post-acute phase of 
the infection [43]. Studies show that patients who spontaneously resolve the infection 
exhibit a strong T-cell response targeting several viral epitopes. In these individuals, the 
post-acute phase is characterized by the absence of HCV RNA from peripheral blood and 
the persistence of stable long-lasting CD8
+
 and CD4
+
 memory T-cell pools after the 
normal decrease in effector T-cell levels following HCV eradication. On the other hand, 
patients in whom the disease progresses to a chronic phase exhibit a weak, narrow 
(targeting very few epitopes), and short-lasting T-cell response to the virus. In these 
individuals, the post-acute (chronic) phase is characterized by persistence of HCV RNA 
in the blood, along with a permanent, almost complete loss of HCV-specific CD4
+
 T-
cells and a dramatic decline in HCV-specific CD8
+
 T-cells which become persistently 
functionally defective. The almost complete absence of CD4
+ 
cells is critical for viral 
persistence, and may also be responsible for the impaired CD8
+
 T-cells’ function [43,44]. 
Here it is important to note that the strength of the CD4
+
 T-cell response in acute 
infection alone is not an accurate predictor of infection outcome, as studies showed that 
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some individuals who managed to mount a strong CD4
+
 T-cell response against HCV 
still developed chronic infection following an unexplained loss of that strong response 
[43]. A graphical depiction of the 3 phases of the T-cell response to HCV and their 
possible outcomes are illustrated in figure 6.          
 
2.2.1.5 Adaptive Immunity – Humoral Response                  
 The second arm of the adaptive immune response against HCV is the humoral 
immune response, the effector response of B-lymphocytes against extracellular microbes 
and microbial toxins mediated by neutralizing antibodies secreted from those cells [31]. 
Unlike CMI where T-cells can only recognize linear epitopes, B-cells can recognize both 
linear and conformational epitopes on their target antigens via their membrane-bound 
antibody receptors. Anti-HCV antibodies become detectable in the patients’ blood around 
4-14 weeks post-infection [15]. The natural targets of these antibodies are epitopes of the 
structural E2 and E1 HCV envelope proteins; however, anti-HCV antibodies targeting 
epitopes of non-structural HCV proteins or their incomplete degradation products 
released from dying hepatocytes are also detected [15,45]. By binding to the E1 and E2 
proteins, anti-HCV neutralizing antibodies would block the entry of HCV into uninfected 
hepatocytes, and facilitate the capture of HCV by macrophages (opsonization) [43]. The 
antibodies can be either isolate-specific, targeting epitopes only found in the viral strain 
infecting the patient, or cross-neutralizing, targeting epitopes found in several strains, 
possibly providing cross-genotype protection [15].  
 In addition to antigen recognition, the activation of protein antigen-specific naïve 
B-cells in peripheral lymphoid organs requires help from effector CD4
+
 T-helper 
lymphocytes. Upon binding their antigen, naïve B-cells internalize the antigen-antibody 
receptor complex, process the internalized protein antigen, and present its epitopes on 
MHC class II molecules for CD4
+
 T-cell recognition. When antigen-specific effector T-
helper cells recognize the presented antigen, they send activatory signals to the antigen-
presenting B-cell in the form of cytokines and CD40-Receptor to CD40-Ligand 
(CD40:CD40L) interactions; these signals stimulate B-cell proliferation, differentiation 
into antibody-secreting plasma cells, and antibody heavy chain isotype switching. 
17 
 
Furthermore, CD4
+
 T-cell help is also required for antibody affinity maturation and 
differentiation of some of the activated B-cells into memory cells [42]. In HCV infection, 
the activated TH1 CD4
+
 effector cells play the aforementioned helper role. The IFN-γ 
secreted by those cells stimulates antibody isotype switching to Immunglobulin G (IgG) 
antibodies, which, upon binding to the structural viral proteins, block viral entry into the 
hepatocytes and promote phagocytosis by macrophages [31]. 
 
2.2.2 Viral Evasion Mechanisms from the Immune Response: 
 In order to persist, HCV has developed several mechanisms by which it can evade 
both arms of the host immune response [13]. First, HCV counteracts the innate immune 
response by interfering with type I IFN production and function and inciting NK and DC 
cell dysfunction [13,14]. Later when the adaptive immune response develops, HCV owes 
its survival mainly to the highly mutable nature of its genome, driven by its RNA-
dependant RNA polymerase, NS5B, which lacks proofreading capability. Furthermore, 
HCV counteracts the effector functions of the cellular immune response by causing the 
exhaustion of T-effector cells and by inducing the activation of regulatory T-cells. It also 
evades the neutralizing actions of anti-HCV antibodies by physically shielding the target 
epitopes of those antibodies by several mechanisms that will be explained in this section 
[13,15].   
 When HCV structural and non-structural proteins are synthesized, they interfere 
with type I IFN production and function by interacting with key components of the signal 
transduction pathways leading to type I IFN and ISG expression, and later with the 
products of the ISG genes themselves [14,29,30]. The NS3/4A viral protease and the NS3 
protein interfere with the expression of IFN-β, where NS3/4A cleaves the adapter 
proteins MAVS (mitochondrial antiviral signaling protein, also known as VISA, Cardif, 
and IPS-1) and TRIF (TIR domain-containing adaptor-inducing IFN-β) that are essential 
components of the RIG-I and TLR3 signaling pathways respectively, and where NS3 
interacts with TBK-1 (TANK binding kinase 1) which is a component of the RIG-I 
signaling pathway, leading to a decrease in IFN-β expression as they accumulate in the 
cells [14,30]. The structural Core protein and NS5A later interfere with the expression of 
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ISGs by inhibiting the activation of the Signal Transducer and Activator of Transcription-
1 (STAT-1) protein of the JAK/STAT pathway that leads to the induction of ISG 
expression. The Core protein was also shown to inhibit the binding of the ISG factor 3 
(ISGF3) transcription factor to the IFN-stimulated response element (ISRE), induce the 
expression of the JAK/STAT pathway inhibitor “Suppressor of Cytokine Signaling 3” 
(SOCS3), and induce the upregulation of protein phosphatase 2 (PP2A), which then 
indirectly attenuates the transcriptional activity of ISGF3 [14,29,30].  
 In addition to interfering with the signal transduction pathways leading to IFN and 
ISG expression, the HCV proteins NS5A and E2 interfere with the products of the ISG 
genes themselves. Studies reported that the NS5A and E2 proteins of HCV genotype 1 
strains both interact with and inhibit Protein Kinase R (PKR), which originally reduces 
protein synthesis in the cell and concurrently inhibits viral replication [14,29,30]. These 
effects on PKR function however have to be validated since reports on them vary 
depending on the HCV isolate and experimental setting, and furthermore, they were not 
consistent in the reports of different research groups [29]. In addition to its interaction 
with PKR, NS5A was also reported to inhibit 2’–5’ oligoadenylate synthetase (OAS) and 
induce the expression of IL-8; which inhibits overall ISG expression [14,29]. Figure 7 
demonstrates the interaction of the aforementioned HCV proteins with the different 
components of the signaling pathways leading to IFN and ISG expression and with the 
products of the ISGs. 
 In addition to counteracting type I IFN production and function, as 
aforementioned, HCV persistence culminates in NK and DC cell dysfunction observed in 
the chronic phase of the infection. Both NK and DC cells start to release cytokines that 
produce an immunosuppressive environment where the CD4
+
 TH1 cell response is 
weakened; encouraging viral persistence. Till now, the underlying molecular mechanisms 
causing NK and DC cell dysfunction have not been fully elucidated. With regard to NK 
cell dysfunction, a study conducted by Nattermann et al. in 2005 concluded that an 
epitope from the HCV core protein is responsible for the stabilization of expression of the 
non-classical HLA class I molecule HLA-E which engages the inhibitory receptor 
NKG2A; this interaction inhibits NK cell-mediated cytotoxicity [41,46]. Another study 
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conducted by Herzer. et al in 2003 suggests that the core protein is also responsible for 
the up-regulation of classical MHC class I expression on the surface of the infected cells 
via the p-53 dependant up-regulation of the transporter associated with antigen 
processing 1 (TAP1) protein, which consequently increases MHC class I expression. This 
enhanced expression leads to the inhibition of NK cell mediated killing of the infected 
hepatocytes [41,47]. With regard to DC cell dysfunction, studies show that the core, NS3, 
NS4, and NS5 HCV proteins are implicated in down-regulating the expression of HLA 
and costimulatory molecules, the reduction of cytokine production, and diminishing the 
DCs’ allostimulatory activity [39]. 
 Prior to the development of the adaptive immune response, several genetic 
variants (quasi-species) of HCV develop and accumulate driven by the faulty replication 
process of HCV RNA that is catalyzed by the error-prone viral NS5B polymerase 
[44,48]. When the adaptive immune response develops, selective immune pressure is 
exerted on the existing viral variants and a significant decline in viral blood titers is 
recorded. At this point, only those variants whose epitopes cannot be recognized by the 
effector cells of the adaptive immune system persist, and the ensuing mutation patterns of 
HCV become directed at altering those epitopes that are amenable to immune 
recognition. This is achieved by mutating the amino acid residues within those epitopes 
that interact with and are recognized by the T-cell receptors and B-cell receptors of 
effector T-cells and B-effector cells respectively, by mutating the amino acid residues 
responsible for anchoring T-cell epitopes in the host’s HLA molecules, and/or by altering 
the proteosomal cleavage sites of the viral proteins thereby interfering with T-cell epitope 
processing and presentation [44,48]. The mutability of those epitopes, however, is 
restricted by the “fitness cost” those mutations will have on the virus; where the mutation 
of epitopes located within functional proteins (e.g. NS3, NS5B) will have a higher fitness 
cost than mutating epitopes located within structural proteins (e.g. E1, E2) as those 
“functional” epitopes could contain key amino acid residues for the functionality of the 
proteins they are located within. Targeting such functional epitopes gives the host an 
advantage and increases the chances of clearing the virus as those epitopes are harder to 
mutate [44,48]. 
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 Besides the mutational escape from recognition by HCV-specific T-effector cells, 
HCV counteracts the cellular immune response against it by causing T-effector cell 
exhaustion; which is defined as the gradual loss of T-effector cell functions due to the 
prolonged exposure to high levels of its cognate antigen [14,41,49]. This might occur due 
to a high viral replication rate exceeding the capacity of containment by the host’s 
immune system [13,49]. One of the major causes of the induction of T-cell exhaustion in 
T-effector cells is the high and/or prolonged expression of inhibitory receptors; and one 
of the major receptors involved is the Programmed Death-1 receptor (PD-1) [49]. Studies 
show that PD-1 expression is upregulated on HCV-specific effector CD8
+
 T-cells in 
chronic HCV infection as a result of prolonged antigenic stimulation. The PD-1 receptor 
on these cells interacts with its ligand PD-Ligand 1 (PD-L1) which is expressed on 
infected hepatocytes preferentially, Kupffer cells, stellate cells, and sinusoidal endothelial 
cells in the liver. This interaction initiates a signaling pathway that culminates in the 
inhibition of the T-cell effector functions and eventually causes apoptosis [14,50]. The 
gradual loss of T-cell effector functions starts by the loss of IL-2 (an important T-cell 
growth factor) secreting activity, followed by the loss of TNF-α secreting activity and 
CD8
+
 T-cell cytotoxicity, then finally by a substantial decrease in IFN-γ secreting activity 
[14,41]. The lack of help from CD4
+
 T-cells aggravates the severity of CD8
+
 T-cell 
exhaustion [14,49]. This correlates with the aforementioned picture of the blood of 
chronically infected Hepatitis C patients, where there is a permanent, almost complete 
loss of HCV-specific CD4
+
 T-cells and a dramatic decline in HCV-specific CD8
+
 T-cells 
that become persistently functionally defective. 
 Another mechanism by which HCV counteracts the cellular immune response is 
the induction of T-regulatory cells [39,51]. T-regulatory cells are characterized by the 
expression of the transcription factor forkhead box P3 (FOXP3), the constitutive 
expression of the IL-2 receptor α-chain (CD25), and the cluster of differentiation-4 
(CD4), and their actions are one of the major mechanisms by which the body maintains 
immune homeostasis, moderates inflammation, and prevents autoimmune reactions in the 
periphery. There are two kinds of T-regulatory (Treg) cells: natural (n) Treg cells that are 
selectively produced in the thymus as a consequence of their TCRs’ high affinity towards 
self antigens, and induced (i) Treg cells that are derived from conventional CD4
+
 T-
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effector cells converted in the periphery via induction by nTreg cells. This conversion is 
induced either directly through cytokine-dependant mechanisms (IL-35, IL-10 or TGF-β) 
or indirectly through DC-mediated mechanisms [39,51]. Like CD4
+
 T-helper cells, Treg 
cells are activated in an antigen-specific manner; which happens when their TCR 
recognizes its cognate epitope in association with MHC class II molecules [52]. When 
they are activated, they suppress the actions of several types of immune cells including 
effector T-cells and B-cells, NK cells, DCs, and macrophages via several mechanisms; 
these include: (1) suppression via inhibitory cytokines (IL-35, IL-10 or TGF-β), (2) 
suppression of T-effector cells by metabolic disruption, such as triggering apoptosis by 
IL-2 deprivation driven by the high expression of the IL-2 receptor on the Treg surface, 
(3) triggering apoptosis of T-effector cells via granzymes A and B and perforin, and (4) 
inhibiting DC maturation and ability to stimulate naïve T-cells [39,51]. A schematic 
representation of the suppressive mechanisms of Tregs is illustrated in figure 8.  
    In HCV infection, studies have shown that the number of Treg cells (both 
nTregs and iTregs) in the liver and peripheral blood of chronically infected patients is 
higher compared to uninfected individuals or those who have spontaneously cleared the 
virus [13,39]. In vitro studies showed that the depletion of CD25
+
 cells (where CD25 is 
another marker expressed by Tregs) from chronic HCV patient blood samples resulted in 
the enhancement of HCV-specific T-effector cell responsiveness[13,14]. While it was 
unclear whether this increased Treg activity is a byproduct of chronic inflammation and 
liver disease or the direct induction by T-regulatory cell epitopes, further investigations 
have uncovered the presence of Treg epitopes (Tregitopes) within HCV structural and 
non-structural proteins, presenting supporting evidence for the specific induction 
hypothesis. It was also found that some of these epitopes exhibit strong homology with 
human self antigens, thus explaining the response and expansion of nTreg cells which are 
normally involved in the suppression of autoimmunity upon encountering self epitopes 
[39]. Furthermore, a recent study by Cusick et al demonstrated that, within the course of 
chronic infection, an immunodominant HCV MHC class II epitope was mutated into a 
Tregitope under the host’s immune pressure [39,53]. These studies elaborate the 
prominent role of Treg cells in the promotion of chronicity development.         
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 In addition to the mutational escape from recognition by neutralizing anti-HCV 
antibodies, HCV evades the humoral immune response by several other mechanisms 
[15,54]. First, HCV can induce the production of non-neutralizing antibodies that 
interfere with the binding of neutralizing anti-HCV antibodies to their target epitopes. 
Studies proposed that a group of epitopes located between amino acids 434-446 in the E2 
protein region, collectively called “epitope II”, trigger the production of non-neutralizing 
antibodies whose binding to their target epitopes blocks the actions of neutralizing 
antibodies that target another adjacent E2 protein region between amino acids 412-426 
called “epitope I” [15,45,54]. Second, HCV can escape the action of neutralizing 
antibodies by binding to lipoproteins while circulating in blood, as it has been 
aforementioned; this association masks the HCV epitopes targeted by those antibodies 
[12,15,54]. Third, the interaction between the hypervariable region 1 (HVR1) -a highly 
variable region within the E2 protein-, high density lipoproteins (HDL), and the 
Scavenger Receptor class B type I (SR-BI) provides protection against neutralizing 
antibodies targeting epitopes outside HVR1. Studies on HCV pseudo-particles (HCVpp) 
have shown that the deletion or mutation of HVR1, the removal of HDL particles, or the 
abolishment of the SR-BI lipid transfer activity obliterates the resistance to antibody-
mediated neutralization [15,54]. Fourth, HCV can shield the target epitopes of 
neutralizing antibodies on the envelope glycoproteins (E1 and E2) by N-glycosylation. 
Studies on HCVpp show that removing glycans from these proteins increases the 
susceptibility of neutralization of HCVpp by anti-HCV antibodies [15,54,55]. Finally, 
HCV can evade recognition by neutralizing anti-bodies by infecting neighboring cells via 
direct cell-to-cell transfer rather than via the receptor-mediated uptake of HCV particles 
released from the infected cells into its surroundings [15,54]. The aforementioned 
mechanisms are illustrated schematically in figure 9. An overall summary of the immune 
response to HCV and the mechanism by which it evades that response is schematically 
represented in figure 10. 
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2.3 HCV Vaccine Development 
2.3.1 Characteristics of an ideal HCV vaccine: 
 In light of the knowledge we have so far on the immune response to HCV, it can 
be inferred that an ideal HCV vaccine would target highly conserved regions in the HCV 
genome. Targeting such regions which are mainly conserved for their important structural 
and functional roles in the HCV life cycle would increase the chances of establishing 
protection against several HCV strains, as it is less likely for the virus to mutate those 
regions in order to evade recognition at low fitness costs. An ideal HCV vaccine would 
also be able to elicit a sustained immune response, one which would successfully create a 
sustained pool of memory cells that can act upon future encounters with the virus. It 
would also be capable of triggering a multi-specific response, as studies have shown that 
targeting several conserved viral epitopes is associated with viral clearance as the virus 
has a further lower chance of immune evasion via mutating several conserved epitopes at 
the same time. Furthermore, an ideal HCV vaccine should be safe and not trigger any 
immunopathology; a goal that has proven to be realistic in the light of previous human 
studies [17].     
 
2.3.2 Challenges facing HCV vaccine development: 
 The process of HCV vaccine design and development was hindered by several 
challenges; some of which have recently been overcome. The first of these challenges 
was to design a vaccine that would overcome the mechanisms by which the virus evades 
the host’s immune response, foremost the highly mutable nature of the virus. The high 
mutation rate of the HCV genome makes the development of a cross-genotype effective 
vaccine very difficult; and for this reason, the development of a prophylactic antibody-
inducing vaccine that targets the E1 and E2 envelope proteins, which are the obvious 
targets for such a vaccine, has been a big challenge, owing to the hyper-variable nature of 
the major antigenic determinants of those proteins [17].       
 The second challenge that faced vaccine development was overcoming certain 
practical obstacles; one of these obstacles was the inability to produce HCV particles in 
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vitro, which made it difficult to understand several aspects of the virus’s life cycle and 
mechanisms of interaction with its host. The first solution to this problem was put forth in 
2003 when HCV pseudo-particles (HCVpp) were developed, which are retroviral and 
lentiviral core particles pseudo-typed with the E1 and E2 structural viral proteins of 
HCV. The study conducted using these particles provided insight on HCV’s entry 
mechanisms into hepatocytes and the antibody-mediated neutralization of HCV particles 
through targeting E1 and E2 epitopes [17,56]. After that in 2005, the first successful 
infection tissue model for HCV was developed, where a unique variant of HCV was 
cultured in human hepatoma cell line Huh-7 cells. This provided further insight into the 
stages of the HCV life cycle in the host’s hepatocytes [17,18]. Another practical obstacle 
that HCV vaccine development faced was that the only animal model available as a 
model for infection and for pre-clinical testing of vaccine candidates was the chimpanzee. 
Although proven useful due to the similarity of its immune response mechanisms to 
humans, the chimpanzee animal model has its financial, practical, and sometimes ethical 
limitations which, in previous studies, allowed only the use of small numbers of this 
model weakening conclusions that could be drawn from those studies’ results. This 
problem has been dealt with by the development and utilization of transgenic humanized 
mouse models; these include models expressing human HLA class I molecules used for 
HCV epitope analysis, and others expressing HCV entry receptors on their hepatocytes 
which allow for the acceleration of the screening process for potential vaccine candidates 
[17,19].   
 Another practical obstacle, particularly facing prophylactic vaccine development, 
is the challenge of designing a clinical trial for testing the efficacy of a candidate 
prophylactic vaccine. In developed countries, the low incidence of HCV infection limits 
the availability of test subjects, except if the study was designed to target intra-venous 
drug users; targeting this test group in the study raises additional practical and ethical 
obstacles on its own. In developing countries where the incidence of HCV is higher, 
careful follow up of the test subjects must be ensured owing to the asymptomatic nature 
of acute infection. Furthermore, since the vaccine in theory may require some time to 
facilitate the clearance of the virus, the timing of the start of IFN therapy must be 
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carefully considered; given the delayed efficacy of the vaccine, the optimal time of 
commencing therapy may be well after that recommended by current guidelines [17].    
 
2.3.3 HCV vaccines in clinical trials: 
 Despite the challenges that faced and still face HCV vaccine development, several 
vaccine studies conducted over the past decade on animal models have yielded promising 
results; a few of these studies have put forth vaccine candidates that have actually entered 
human clinical testing [17,19]. Most of these studies focused on the evaluation and 
development of therapeutic vaccine candidates, which aim at preventing/alleviating the 
complications associated with disease progression and assisting in the eradication of the 
virus in combination with standard therapy. A smaller number of those studies have 
focused on the evaluation and development of prophylactic vaccines, which aim at 
immunizing the host to prevent infection. With regard to pre-clinical testing (i.e. in 
animal models), most studies showed that the developed vaccine candidates were indeed 
able to elicit HCV specific immune responses, which were able to alter the course of 
subsequent challenge infections by allowing better control over viral replication and 
increasing the likelihood of clearing the virus [17,57]. HCV vaccine candidates currently 
undergoing clinical trials are extensively reviewed in Halliday et al. 2011 [17]. Examples 
of those vaccines and the results of their clinical testing are listed in table 2.   
 
2.4 Computational Vaccinology and Epitope-driven vaccine design 
 In conjunction with the ever increasing applications of bioinformatics in 
biotechnology, immunoinformatics, the branch of bioinformatics concerned with 
immunology and vaccinology, has allowed researchers to uncover important functional 
information impacting molecular immunology; furthermore, it has opened the door for 
the revolutionary field of Computational Vaccinology [58]. Computational vaccinology 
refers to the computer-aided design of vaccines, where immunoinformatics and 
bioinformatics tools are used to identify potential vaccine targets within a target genome 
in silico before being empirically tested and validated [59]. There are generally two 
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approaches for vaccine design computationally, the first being the antigen-driven 
approach, where the target genome is screened with the aim of identifying protective 
antigens; for example, a pathogen’s genome can be screened for sequence patterns 
characteristic of cell surface-expressed proteins that can potentially induce humoral 
immunity. The second approach is the epitope-driven one, where the target genome is 
scanned with the aim of identifying immunogenic T-cell and B-cell epitopes; these 
epitopes are then either themselves synthesized in an appropriate form and packaged in 
an appropriate delivery vehicle to be used as a vaccine (e.g. peptide vaccine or DNA 
vaccine), or can be used to identify potentially protective whole protein antigens from the 
target genome which can be used as vaccine targets (referred to as “fishing for antigens 
using epitopes as bait”) [60]. The total repertoire of protective epitopes (T-cell and B-
cell) derived from a target genome/proteome is referred to as the Immunome [60]. 
   Over the past decade, the process of epitope-driven vaccine design (also known 
as Immunome-Derived vaccine (IDV) design) has witnessed several applications in 
cancer and infectious disease vaccine development, bolstered by the availability of a wide 
variety of specialized immunoinformatic epitope-mapping (immunome-mining) tools, 
which are designed for the in silico identification of T-cell and B-cell epitopes from the 
target genome/proteome [23,60]. There is a wide variety of efficient algorithms 
developed for T-cell epitope mapping which have found application in several research 
laboratories in the field of drug discovery; however, fewer algorithms have been 
developed for B-cell epitope mapping which are not very efficient at epitope prediction. 
This is due to the nature of B-cell and T-cell epitopes, where the linear and shorter form 
of T-cell epitopes makes it simpler to develop algorithms for their prediction compared to 
B-cell epitopes which may be conformational in nature [59-61]. 
   
2.4.1 Advantages of immunoinformatics-guided epitope-driven vaccine design: 
 In comparison to traditional vaccines, IDVs possess the potential of being safer 
and more effective [23]. The higher potential effectiveness of IDVs is due to the fact that 
the vaccine is designed to focus the immune response on the most immunogenic and 
essential epitopes of the target pathogen or neoplasm. With regard to safety, IDVs are 
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considered safer than live attenuated and vector vaccines; furthermore, since IDVs can be 
designed in a minimalist form to contain only the target epitopes rather than whole 
protein antigens, they may be able to avoid some of the health hazards associated with 
some of those antigens. For example, despite its high cross-genotype conservancy, it was 
found that the Core protein of HCV is able to induce hepatocellular carcinoma in 
transgenic mice and cause steatosis formation [25]. Accordingly, the use of immunogenic 
epitopes from the core rather than the core antigen itself in a vaccine would be considered 
safer. 
 Compared to the traditional empirical method where scientists used to isolate 
target proteins (antigens) and process them to extract and test all potentially 
immunogenic epitopes [60], epitope-mapping tools allow for the in silico identification of 
the most immunogenic of those epitopes before further testing is carried out in the wet 
lab. This saves the time and costs associated with testing all potentially immunogenic 
epitopes empirically before selecting the most immunogenic ones that can actually be 
included in a vaccine. Furthermore, while the empirical method may result in some 
important epitopes being overlooked due to imprecise protein digestion, epitope-mapping 
tools may avoid that if an efficient algorithm is used to scrutinize all possible “epitope 
frames” within a target protein sequence [58,61]. In addition to being able to map 
epitopes in silico, immunoinformatcs/bioinformatics tools also allow for homology 
testing of those epitopes against the human genome with the aim of avoiding the use of 
epitopes that have homologous sequences in the human genome. If used, such epitopes 
may trigger a suppressive immune reaction due to the immune system being tolerant to 
them, or may trigger an autoimmune reaction against self. Accordingly, avoiding the use 
of such epitopes potentially also makes the vaccine safer and more effective [23,60]. 
              
2.4.2 Types of T-cell epitope-mapping tools: 
 In the past, T-cell epitope mapping algorithms were designed to predict T-cell 
epitopes directly, based on the hypothesis that T-cell epitopes are amphipathic structures 
with a hydrophilic side facing the T-cell receptor (TCR) of T-cells, and a hydrophobic 
side facing the binding groove of the MHC molecule; such algorithms were referred to as 
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“direct” methods of epitope prediction [58]. Currently utilized T-cell epitope mapping 
algorithms however are those designed to predict T-cell epitopes based on the binding 
specificities of the MHC molecules rather than the molecular structures of the epitopes 
themselves; such methods are referred to as the “indirect” methods of prediction, and can 
be classified according to their prediction approaches into: motif-based methods, matrix-
based methods, machine-learning-based methods, and ab intio methods [58]. 
 In motif-based methods, epitope prediction algorithms predict MHC binders by 
screening for specific amino acid residues, called “anchor” residues, in the target peptide 
sequence [58,62]. Anchor amino acid residues of T-cell epitopes interact with 
polymorphic amino acid residues in MHC molecules which are located within certain 
‘pockets’ in the MHC epitope-binding region (explained in detail in the next section); 
these polymorphic residues differ from one MHC molecule to the other, and 
consequently the nature of the anchor residues of the T-cell epitopes they bind. The 
recurrent pattern of anchor residues that bind each MHC molecule is referred to as a 
“motif” [62]. Although proven valuable, the in vitro validation of the in silico results 
generated by these methods showed that they are relatively nonspecific, as they predicted 
epitopes that did not bind to their respective MHC alleles or were not immunogenic, and 
insensitive, as they failed to predict true binders that did not bear the anchor residues 
however bore 2ry anchor non-conserved residues at other locations in the peptides 
[58,62]. Specificity of a prediction algorithm is a measure of its efficiency in excluding 
non-binder epitopes, while sensitivity is a measure of its efficiency in including true 
binders in its predictions [62].  
 In contrast to the motif-based approaches which assume that only anchor amino 
acid residues contribute to epitope binding, matrix-based approaches on the other hand 
account for the contributions of all amino acids of a target epitope in their predictions 
[62]. When constructing a matrix-based epitope prediction tool, a reliable training set of 
epitope-binding data is first identified. Then quantitative or frequency matricies for each 
MHC molecule to be included in the predictions are constructed by analyzing the 
distribution of amino acid frequencies at each position in the binding cleft of the MHC 
molecule and/or the influence of each amino acid binding at each position on the overall 
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binding affinity of the epitope, and then using the outcome of the analysis to assign a 
numerical value for every one of those amino acids at their respective binding positions. 
The prediction of the binding affinity of new epitopes is then carried out by looking up 
the values assigned for each amino acid in the epitope relative to its position in the MHC 
molecule in the matrix, and then either adding or multiplying these values to obtain an 
overall score for the peptide that is used to predict its likelihood of binding relative to a 
predetermined cut-off value [62,63]. Matrix-based approaches perform better compared 
to motif-based approaches; however, they handle data in a ‘linear’ manner, where they 
consider the individual contributions of each amino acid residue in the epitope to epitope 
binding independently; this is not the case in reality, as epitope binding is not determined 
by the simple summation of the contributions of each amino acid residue at each position 
in the target epitope [58]. 
 While matrix-based prediction approaches cannot handle non-linearity in data, 
machine learning based approaches can. A limitation of such approaches is, however, that 
they require a relatively large MHC binder training dataset for their construction, which 
is available for a small, albeit increasing, number of MHC molecules/alleles. There are 
several examples of machine-learning techniques employed in T-cell epitope prediction 
algorithms such as artificial neural networks (ANN), Hidden Markov Models (HMM), 
and Support Vector Machines (SVM) [58]. The last approach for T-cell epitope 
prediction is the ab initio approach, which functions by predicting binders to an MHC 
molecule using a structural model of that molecule without the requirement for a training 
dataset. This approach however requires an elucidated 3D structural model of the MHC 
molecule of interest as well as high computational power for performing the analysis 
[58].  
 
2.5 The Human Leukocyte Antigen 
 As aforementioned, the Major Histocompatibility Complex (MHC) molecules are 
specialized proteins encoded by genes in the Major Histocompatibility Complex locus 
found in the chromosomes of all vertebrates, their role is to display peptide fragments 
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(epitopes) of digested protein antigens on cell surfaces to be recognized by T-
lymphocytes leading to their activation; class I MHC molecules are expressed on all 
nucleated cells and activate CD8
+
 T-cytotoxic lymphocytes, while class II MHC 
molecules are only expressed in antigen presenting cells and activate CD4
+
 T-
lymphocytes. In humans, the major histocompatibility complex is also known as the 
Human Leukocyte Antigen (HLA), and is present on the short arm of chromosome 6 
[36,64].  
 
2.5.1 HLA molecules: 
 HLA molecules are glycosylated heterodimeric transmembrane proteins 
composed of two non-covalently associated polypeptide chains; in HLA class II 
molecules, both polypeptide chains are encoded by HLA class II genes and are called 
chains α and β, while in HLA class I molecules only one of the chains is encoded by 
HLA class I genes, called the heavy α chain, while the other chain in not encoded by the 
HLA locus and called the light β2-microglobin chain [36,64].  The overall tertiary 
structure of HLA molecules can be divided into four parts: an extracellular N-terminal 
peptide (epitope)-binding region, an extracellular Immuno-globulin (Ig)-like region, a 
hydrophobic transmembrane region, and finally a small C-terminal cytoplasmic region. 
The epitope binding region is composed of two α-helices resting on an eight-stranded β-
pleated sheet forming a cleft within which epitopes bind for presentation to T-
lymphocytes in a linear conformation. In HLA class II molecules, the binding cleft is 
composed of the N-terminal domains of the α and β chains called α1 and β1 respectively, 
where each domain is formed of about 90 amino acids and contributes to half of the 
structure; the ends of the binding cleft are open, which is why HLA class II epitopes tend 
to have a variable length that can reach 30 amino acids, typically however falling within 
the range of 13 to 25 amino acids. In HLA class I molecules on the other hand, the 
binding cleft is composed of two N-terminal domains of the α chain called α1 and α2; in 
contrast to class II molecules, the ends of the binding-cleft are closed, restricting the size 
of HLA class I epitopes to 8-11 amino acids[36,64]. A third domain of the α chain, called 
α3, forms the Ig-like extracellular region; and is responsible for interacting with the CD8 
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molecule of the T-cytotoxic lymphocytes. In class II molecules, the same function is 
performed by the β2 region of the β chain, which forms the Ig-like domain that interacts 
with the CD4 molecule of T-helper lymphocytes [36,64].  
 With regard to HLA class II epitopes, the affinity and specificity with which they 
bind to the epitope-binding cleft of the HLA class II molecule is mainly determined by a 
core region in those epitopes made up of 9 amino acids [65]; the remaining AA residues 
flanking the core region also assist in peptide binding by enhancing the binding affinity 
and stability of the molecular complex [66]. The peptide backbone of the core region 
interacts with conserved residues in the MHC binding-site via hydrogen bonds, which 
maintains the peptide in a linear conformation with the core region of the peptide having 
a conserved secondary structure resembling that of a polyproline chain [64,67]. In this 
conformation, side chains of AA residues 1, 4, 6, and 9 of the core region of the peptide 
are directed ‘into’ the binding-cleft; where they interact with four major pockets 
distinctive of the MHC class II binding-site. The properties of these pockets vary from 
one MHC class II isotype (molecule) to the other, and determine the specificity with 
which the epitopes bind to the binding-groove. Furthermore, the interaction of the stated 
AA residues with the pockets enhances the stability of the molecular complex; which is 
why these residues are called the ‘anchor’ residues of the peptide [65-67]. Side chains of 
other AA residues in the core region of the peptide also interact with different AA 
residues in the β-pleated sheet floor and α-helix walls of the binding groove via hydrogen 
bonds and salt-bridges; interactions which also contribute to the binding affinity of the 
peptide. For the peptide to be identified by its antigen-specific T-helper cell, side chains 
of certain AA residues from the core region protrude upwards away from the binding 
cleft to interact with and be recognized by the T-cell receptor (TCR) of the TH-cell. The 
TCR, however, does not only interact with those residues, but it also interacts with 
polymorphic AA residues of the α-helices of the MHC itself [36,64]. A 3D illustration of 
an epitope associated with an HLA class II molecule binding cleft is presented in figure 
11. 
 HLA class I epitopes are accommodated in the binding groove of HLA class I 
molecules by anchoring the ends of the epitope and allowing its middle portion to bulge 
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upwards. Amino acid side chains of anchor residues at the N and C termini of the 
epitopes –usually the first and last two- are directed “downwards” into the binding cleft 
where they interact with amino acid residues found within pockets in the HLA binding 
cleft, similar to the case of the binding of HLA class II epitopes to their binding cleft. 
Different HLA molecules encoded by different genes have different pockets, and hence 
can bind to different peptides. Furthermore, different HLA molecules encoded by 
different alleles of a given HLA class I gene also show minor differences in their 
specificity towards anchor residues [64]. Typically, the main contribution to the binding 
affinity of an epitope is provided by the residues at position 2 and at the C-terminus of 
the peptide, which interact with 2 pockets in the binding cleft called “B” and “F” 
respectively [68]. Amino acids in the middle of the epitope are directed upwards where 
they interact with the TCR of T-cytotoxic lymphocytes; determining the specificity and 
affinity with which the TCR binds to the HLA-peptide complex. These residues also 
partly contribute to the peptide binding affinity to the HLA molecule. If it is 
conformationally possible, HLA class I molecules can accommodate epitopes longer than 
10 amino acids if their central amino acid residues can bugle upwards [64]. 
 
2.5.2 HLA genes: 
 The α and β chains of the HLA class II molecules are encoded by multiple 
functional genes found in the MHC locus on chromosome 6; these genes are located 
within three regions in this locus, namely DR, DQ, and DP. The DP region harbors genes 
for two α and two β HLA chains; of which only α1 and β1 are functional. The same is 
true for the DQ region; except that it includes a third non-functional gene for a β HLA 
chain (β3). The DR region on the other hand is different; where it harbors only one gene 
for an α HLA chain that is monomorphic in the region encoding for the peptide-binding 
α1 domain of the α chain, and 9 polymorphic genes for HLA β chains. Of the nine, only 
genes number 1, 3, 4, and 5 are functional. β chain genes numbers 1 and 9 are present in 
all individuals, but the presence or absence of genes 2-8 in DR varies from one individual 
to the other [36,64]. When translated, the α and β chains encoded by genes of the same 
region (e.g. DR) most usually form the HLA molecule; and on rare occasions do the α 
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and β chains encoded by genes of different regions (e.g. DR and DQ) form the molecule. 
Mixing between α and β chains of the same region but encoded on genes from different 
parental origin is also common. Both paternal and maternal chromosomes are co-
dominantly expressed [36,64]. 
 As for HLA class I molecules, the α chain is encoded by multiple functional genes 
also found in the HLA locus on chromosome 6. In contrast to HLA class II however, the 
β2-microglobin chain is encoded by an invariant gene on chromosome 15. The genes 
encoding for the α chain are denoted HLA-A, B, and C. Just like HLA class II genes, 
maternal and paternal HLA class I genes are co-dominantly expressed; which means that 
for each individual there can be six variants of the HLA class I molecule expressed on all 
nucleated body cells. However, the levels of expression of the different HLA class I 
genes differ. For example, 20-50% of individuals depending on the race do not seem 
express a functional HLA-C protein [36,64].  
 
2.5.3 HLA classification and nomenclature: 
 In the past, the characterization of HLA variants was performed by serological 
typing [69,70]. This lead to the classification of HLA molecules into serotypes, where a 
serotype is defined as the HLA molecule(s) that are detected by an available respective 
antibody. The serological typing method cannot, however, identify all existing HLA 
genotypes individually. This is because the available HLA-specific antibodies are smaller 
in number compared to the ever increasing number of HLA alleles, and are moreover 
hard to detect. Furthermore, HLA antibodies cannot detect null HLA alleles which are 
not expressed. As a result of that, each defined HLA serotype usually describes several 
HLA allelic variants. Furthermore, some of the defined HLA serotypes describe “broad 
antigens” as they are further sub-categorized into “split antigens” owing to the increase in 
sensitivity and refinement of Serotyping methods over the years which lead to the 
identification of new anti-HLA antibodies [71]. As a result of lower specificity, broad 
antigen serotypes exhibit cross-reactivity with the split antigen serotypes; for example, 
the HLA-A9 serotype describes a broad antigen whose antibody can detect HLA-A23 and 
A24 split antigens [71,72]. 
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    When HLA DNA typing methods were developed, such as the PCR-based 
sequence specific oligonucleotide probing (PCR-SSOP), sequence-specific priming 
(PCR-SSP), and sequencing-based typing (PCR-SBT) methods, a more specific 
nomenclature system for the characterization of HLA genes and alleles was developed 
[69,71,72]. Assigning names for new HLA genes and alleles is performed by the World 
Health Organization’s (WHO) Nomenclature Committee for Factors of the HLA System 
using a specific format [71]. Based on the latest update of the format of the nomenclature 
system, HLA alleles are to be denoted by an “HLA” prefix, followed by the gene name, 
followed by 4 fields of digits, and finally a one letter suffix, with all components 
separated by specific separators which are: a hyphen between the HLA prefix and the 
gene name, an asterix between the gene name and the digit fields, and finally colons 
between the digit fields themselves (e.g. HLA-A*02:01:01:02N). The first two digits in 
the digit fields are used to describe the allele family, which usually corresponds to the 
serotype of the HLA. The third and fourth digits describe HLA alleles whose sequences 
harbor non-synonymous mutations in the expressed protein sequence (exons), mainly in 
the regions coding for the epitope-binding site of the molecule, and are assigned based on 
the order by which the sequences of the alleles have been elucidated. Synonymous 
mutations that occur in the exons are described by the fifth and sixth digits of the name. 
The seventh and eighth digits are used to describe mutations in the introns or the 5’ and 
3’ untranslated regions of the alleles. Finally, the one letter suffix is used to describe the 
expression status of the allele (e.g. “N” refers to “null allele”, while “L” refers to “Low 
expression level”) [73,74]. Depending on the DNA typing method utilized, the resolution 
of HLA typing can vary between low resolution typing, which characterizes the allele 
with respect to the allele family only (first digits field), to high resolution typing, which 
characterizes individual alleles based on the amino acid sequences of the their epitope-
binding sites (first two digit fields), to “allelic” resolution, which characterizes the full 
DNA sequence of the typed allele [73].       
 In addition to the serological and genetic nomenclature systems, HLA variants 
can be also classified based on the structural features of the epitopes they bind. X-ray 
crystallographic analysis of the epitope-binding regions of HLA molecules have shown 
that their polymorphic residues are located within ‘pockets’ in the cleft and are 
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responsible for determining the binding specificity of the HLA molecule by engaging 
certain anchor residues in their target epitopes. Analysis of the amino-acid sequences of 
the epitope repertoire of each HLA molecule uncovered a frequent occurrence of certain 
amino acid residues in these anchor positions; the recurring patterns were termed 
“motifs” [62,75]. Although each HLA molecule has its own binding specificity and 
anchor motifs, studies have shown that several HLA molecules within the same class 
(class I or class II) share similar binding specificities with regard to those motifs. These 
molecules are said to belong to the same ‘Supertype’, and the broad anchor motif that 
describes the anchor motifs of each HLA member of the supertype cluster is referred to 
as the ‘Supermotif’ [75,76]. For example, the HLA class I supertype A2, which includes 
the HLA alleles A*02:01, A*02:02, A*02:03 and others, has a supermotif defined by 
aliphatic hydrophobic residues (e.g. Alanine, Threonine) at position 2 and the C-terminus 
of the target epitope.  
   In contrast to the serological and genetic nomenclature systems, HLA supertype 
assignments are not standardized. Several research groups have defined HLA supertypes 
based on the epitope-binding data of individual HLA alleles, which was generated via 
different computational and empirical methods; consequently, no consensus assignment 
of individual HLA alleles to a particular supertype exists [75,77]. With regard to HLA 
class I alleles, the research group of Sidney and Sette [75,76,78]  classified the HLA-A 
and HLA-B loci alleles into 9 major supertypes: four for gene A, namely A1, A2, A3, and 
A24, and five for gene B, namely B7, B44, B27, B58, and B62. This classification is in 
general agreement with the results of others performed by the research groups of Tong 
[79], Lund [80], and Hertz [81], with variations, if present, in the assignment of 
individual alleles to supertypes and the splitting of supertypes to smaller groups; for 
example, Lund et al. suggested the splitting of some of the alleles in the A1 supertype 
into a new A26 supertype [62].  
 The functional categorization of HLA molecules into supertypes is very beneficial 
for epitope-driven vaccine design. With regard to HLA class I supertypes, it was found 
that 6 of the 9 supertypes proposed by the Sidney and Sette research group, namely A1, 
A2, A3, A24, B7, and B44, account for most of the HLA-A and HLA-B alleles of five 
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major ethnic groups in the general population (over 85% of HLA-A alleles and 40% of 
HLA-B alleles in the Caucasian, North American Black, Hispanic, Chinese, and Japanese 
ethnic groups). Practically, epitopes of those 6 supertypes can afford an average coverage 
of 99.3% of any population, which means that an epitope-driven vaccine targeting 
epitopes of all those supertypes at once can potentially be effective in any vaccinated 
population [78]. 
 
2.6 The iVAX Immunoinformatics toolkit 
 iVAX (EpiVax Inc., RI, USA) is a web-based suite of immunoinformatics tools  
for designing genome-derived T-cell epitope-driven vaccines [82]. The key tool of the 
iVAX toolkit is called EpiMatrix, a frequency matrix-based T-cell epitope mapping tool 
that has been used and validated for over a decade in in vitro and in vivo studies [23]. In 
this section, a description of how EpiMatrix and the other tools of the iVAX toolkit that 
were used in this project work will be discussed. 
 
2.6.1 EpiMatrix: 
     Similar to other matrix-based T-cell epitope mapping tools, the EpiMatrix 
algorithm is based on a collection of matrices for a set of class I and class II HLA 
molecules (from here-on referred to also as ‘HLA alleles’ for simplicity instead of saying 
‘HLA molecule coded by a given allele’). Within each matrix, a score is given to each of 
the 20 amino acids at each pocket (position) in the binding cleft of the HLA molecule 
based on the empirically-determined paucity or preponderance of that amino acid at that 
position in a large set of natural epitopes of that molecule [23,78]. An example of one of 
EpiMatrix’s frequency matricies is illustrated in figure 12. In a typical analysis aiming to 
predict 9-mer binder epitopes, an input protein sequence is parsed into 9 amino acid 
peptide frames, where each frame overlaps the last by 8 amino acids, and each frame is 
scored for binding to a specific HLA allele additively using frequency scores derived 
from the matrix corresponding to that allele, giving an allele-specific “raw score”. To be 
able to compare binding affinities of a given peptide across several different alleles, the 
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allele specific raw score is normalized according to a score distribution derived from a 
randomly generated large set of peptides to give a Z-score (assessment score).  
 According to the Z-score scale, an epitope scoring 1.64 or higher is considered to 
be a potential binder, as peptides scoring 1.64 or higher are usually from amongst the top 
5% binders of a randomly analyzed peptide set; hence, such an epitope is considered 
potentially immunogenic and is a good candidate for further testing. Furthermore, 
epitopes scoring 2.32 or higher correspond to the top 1% binders of any analyzed peptide 
set, and hence are the best candidates to be carried forward for further analysis in terms 
of immunogenicity. Converting allele specific raw scores to Z-scores makes easier the 
identification of promiscuous epitopes [23,78].  
 
2.6.2 Conservatrix: 
 When designing vaccines against pathogens with highly mutable genomes such as 
HCV and the Human Immunodeficiency virus (HIV), it is disadvantageous to include 
highly mutable epitopes in the vaccine, despite the fact that they may be highly 
immunogenic, as the pathogen will be able to escape the immune response directed 
against those epitopes by mutating them. Accordingly, vaccine design must be directed 
towards including highly conserved and immunogenic epitope targets in the vaccine; 
such epitopes are usually parts of conserved amino acid sequences that play an important 
structural or functional role in the pathogen’s life cycle and are less likely to be mutated 
in the course of the pathogen’s evolution. To identify those epitopes, the iVAX toolkit 
employs the “Conservatrix” tool, which parses input amino acid sequences into frames of 
user-defined length, then scans the input dataset, which harbors several sequences 
obtained from the different pathogen’s strains, for matching segments. The tool then 
calculates the percent conservation of the analyzed segments across the input protein 
sequences [23].   
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2.6.3 EpiAssembler: 
 EpiAssembler is a tool that constructs MHC class II epitopes in an extended form 
called “Immunogenic Consensus Sequence (ICS)” peptides using highly conserved, 
promiscuously immunogenic, and overlapping MHC class II epitopes that were scored 
for binding to MHC class II molecules using EpiMatrix and analyzed for conservancy 
using Conservatrix [23]. EpiAssembler works by first selecting highly conserved and 
promiscuously immunogenic (having Z-scores ≥ 1.64 for more than one MHC class II 
alleles) 9-mer peptides, and then iteratively searching the rest of the EpiMatrix results 
dataset for other highly conserved and promiscuously immunogenic peptides that overlap 
the N- and C-termini of the initial “core” peptide in order to use those peptides to extent 
the length of the constructed ICS. In the case where more than one overlapping peptides 
are identified, the one with the highest conservancy and promiscuous immunogenicity is 
selected by EpiAssembler to extend the ICS. This process of ICS extension is repeated 
until either no more overlapping peptides are found in the dataset, or until the user-
defined ICS length is reached [23,83]. An illustration of how EpiAssembler works is 
given in figure 13. 
 Apart from choosing the most conserved and promiscuously immunogenic MHC 
class II epitopes for vaccine design, which would potentially increase the vaccine’s target 
population coverage and its ability to trigger a protective immune response, 
EpiAssembler has the advantage of enabling the design of a vaccine construct that 
delivers an ‘antigenic payload’ which would otherwise be very expensive to develop 
using conventional methods, as different variants of each antigen will have to be included 
in the vaccine [23].        
 
2.6.4 JanusMatrix: 
 As aforementioned, the inclusion of T-cell epitopes in the vaccine construct that 
bear similarity to autologous epitopes from the human proteome may either result in 
triggering an autoimmune response against self, or in triggering a suppressive immune 
response that would decrease the vaccine’s efficiency; accordingly, it is advised that such 
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epitopes not be included in the vaccine [23,60]. Epitopes that are putatively cross-reactive 
with self can be identified in silico using the JanusMatrix tool.    
 JanusMatrix is a tool that identifies T-cell epitopes from the human proteome 
(genome), protein sequences of the human microbiome, and/or human bacterial and viral 
pathogen proteomes that are potentially cross-reactive with T-cell epitopes of interest; 
specifically by identifying T-cell epitopes from those proteomes and protein sequences 
that bear identical T-cell receptor (TCR)-facing amino acid residues to those of the 
epitopes of interest [84]. The tool works by dividing putative 9mer T-cell epitopes 
predicted by the EpiMatrix tool into TCR-facing residues (referred to also as the 
“epitope”) and HLA-binding residues (referred to as the “agretope”) based on rules 
defined in literature, and then searching for potentially cross-reactive epitopes across 
user-selected protein databases from those that have been pre-uploaded to the tool that 
bear identical TCR-facing residues and are predicted to bind the same HLA molecule as 
the putative T-cell epitopes of interest, regardless of the existence of discrepancies in the 
agretope [84]. According to literature, the TCR-facing residues of HLA class I 9mer 
epitopes are residues number 4, 5, 6, 7, and 8, while those of HLA class II epitopes are 2, 
3, 5, 7, and 8 [85]. Figure 14 displays a 3D model of a T-cell epitope in association with 
both the HLA molecule and the TCR. 
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3. PROJECT AIM & OBJECTIVES 
 
 The aim of this project is to identify, in silico, a set of highly immunogenic and 
conserved T-cell epitopes from within the HCV-4 proteome as putative targets for an 
epitope-driven vaccine for HCV-4. The objectives of the project are as follows: 
 
1. To use the iVAX immunoinformatics toolkit (EpiVax Inc., RI, USA) to identify 
highly conserved and immunogenic T-cell epitopes from within 46 non-redundant 
HCV-4 proteomes, and assess their homology to epitopes derived from the human 
genome.  
 
2. To retrospectively validate the HLA binding predictions for those epitopes by 
searching for records of HLA binding assays or T-cell assays performed on those 
epitopes in previous literature in the context of other HCV genotypes on the 
Immune Epitope Database (IEDB). 
 
3. To perform a pilot in vitro HLA binding assay on selected HLA class II ICS 
peptides (epitopes), and compare the results with those of the retrospective 
validations for the same peptides. 
 
4. To assess the conservation of a selected set of the identified epitopes in newly 
partially re-sequenced HCV genomes derived from the Egyptian Population as an 
assessment of the HCV subtype coverage that these epitopes would provide if 
they were to be included in population-specific vaccine targeting the Egyptian 
population. 
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4. METHODOLOGY 
 
4.1 HCV-4 Genomes Collection 
 46 non-redundant HCV genotype 4 full genomic sequences were retrieved from 
the Los Alamos HCV sequence database (LANL) [86]; their accession numbers were also 
matched on the Genbank database, these being: DQ418785, DQ418782, DQ418783, 
DQ418784, DQ418787; DQ418788; DQ418789, DQ516084, DQ988073, DQ988074, 
DQ988075, DQ988076, DQ988077, DQ988078, DQ988079, GU814265, NC_009825, 
FJ025854, FJ025855, FJ025856, FJ462435, FJ462436, DQ418786, DQ516083, 
EU392172, FJ462437, EF589160, EF589161, EU392169, EU392170, EU392174, 
EU392175, FJ462432, EU392171, EU392173, FJ462438, FJ839870, FJ462433, 
FJ462441, FJ462440, FJ462431, FJ462434, FJ462439, FJ839869, HQ537008, and 
HQ537009. The amino acid sequences of the HCV polyprotein genes corresponding to 
those genomic sequences were downloaded in FASTA format and modified to a format 
compatible with the iVAX toolkit server, whereby all the single letter ambiguous amino 
acid codes B, Z, and J, which stand for Asparagine/Aspartic acid, Glutamine/Glutamic 
acid, and Leucine/Isoleucine, respectively, and the single letter amino acid codes U and 
O, which stand for the 21
st
 and 22
nd
 identified amino acid residues Selenocysteine and 
Pyrrolysine, respectively, were replaced with the single letter ambiguous amino acid code 
X, which declares the amino acid residue as unspecified. After their modification, the 46 
protein sequences where uploaded to the iVAX toolkit’s website 
(https://ocs.epivax.com/ivax_ntd/) as a single file bearing the “.PEP” file extension that is 
required for the sequences to be identified as proteins. More information on the 46 HCV-
4 sequences is provided in table 3. 
 
4.2 HLA Class I and Class II Epitopes Identification and Selection 
     After uploading the sequences onto the iVAX server, the tools of the iVAX-
toolkit were used in concession to identify and narrow down the selection of HLA class I 
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and II epitopes from the HCV-4 sequences to a set that can be putatively included in the 
final vaccine product. 
 
4.2.1 Conservation Analysis: 
 The Conservatrix tool was used to parse the input sequences into 9-mer peptide 
frames and analyze the conservation of those frames across the 46 amino acid sequences. 
The 9-mer peptide frames represent putative HLA class I epitopes and the core regions of 
putative HLA class II epitopes. 
  
4.2.2 HLA Class I and II Epitope Prediction: 
 After performing the conservation analysis, the EpiMatrix tool was used to 
predict the binding of the parsed 9-mer frames to the six HLA class I alleles A*01:01, 
A*02:01, A*03:01, A*24:02, B*07:02, and B*44:03 which belong to the 6 supertypes 
A1, A2, A3, A24, B7, and B44 respectively, and the eight HLA class II DR alleles 
DRB1*01:01, DRB1*03:01, DRB1*04:01, DRB1*07:01, DRB1*08:01, DRB1*11:01, 
DRB1*13:01, and DRB1*15:01. The phenotypic frequencies of those HLA class I and II 
alleles cover >90% of any human population regardless of its ethnic origin, potentially 
allowing the vaccine to be effective in any vaccinated population [78,95]. It is important 
to note here that the DR molecules are referred to by the names of the DRB1 alleles 
which code for the polymorphic β chains of the molecules.   
 After obtaining the results of the analysis, only those peptide frames that have Z-
scores ≥ 1.64 for binding to a HLA class I allele and are fully conserved in at least 42 out 
of the 46 sequences (>90% conservancy) were chosen for further analysis. As for peptide 
frames scored for binding to HLA class II alleles, the EpiAssembler tool was used to 
construct extended Immunogenic Consensus Sequence peptides (ICS) from those frames. 
Before executing the analysis, EpiAssembler was set to only extend core peptides with 
peptides that overlap with it by at least 4 amino acids at either the N- or C-termini, and to 
extend the ICS to a maximum length of 21 amino acids. It was also set to construct ICS 
peptides whose component core 9-mer segments cover, collectively, at least 90% of the 
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46 uploaded HCV polyprotein sequences in terms of conservation, and to only accept the 
construction of ICS peptides that have a minimum EpiMatrix Cluster Immunogenicity 
score of 10. The EpiMatrix Cluster Immunogenicity score is derived from the number of 
EpiMatrix “hits” (scores ≥ 1.64 per allele) normalized for the length of the ICS peptide; a 
score of ICS 10 or higher indicates that the ICS possesses a significant immunogenic 
potential. 
 
4.2.3 Homology to Self Analysis: 
 In order to avoid a suppressive immune response to the sequences selected for the 
vaccine, or autoimmune adverse effects due to the induction of immune response to 
epitopes cross-conserved with self in the final vaccine product, the selected HLA class I 
epitopes and HLA class II ICS peptides were assessed for homology to the human 
genome using the JanusMatrix tool, where the reviewed human Uniprot protein database 
that was per-uploaded to the tool server was scanned for cross-reactive epitopes within 
the human genome that bear identical TCR-facing AA residues and are predicted by 
EpiMatrix to bind to the same alleles for which the analyzed epitopes are predicted to 
bind to. 
 
4.3 Epitope Mapping on the HCV Genome 
 The regions of the HCV genome harboring the selected epitopes and their exact 
locations were determined by aligning the amino acid sequences of the epitopes with the 
amino acid sequence of the polyprotein gene of the HCV genotype I reference strain H77 
(Accession number: NC_004102) using the “Sequence locator” tool of the Los Alamos 
HCV sequence database (LANL) [86].  
 
4.4 Retrospective Validation of the EpiMatrix Predictions 
 To investigate whether the selected HLA class I epitopes and constructed HLA 
class II ICS peptides were tested before in vitro in previous literature for HLA binding, 
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cell-surface presentation, and/or their ability to elicit an immune response, the Immune 
Epitope Database (IEDB), a large repository of immune epitope data manually curated 
from peer reviewed literature, patents, and direct submissions from companies and 
institutions [21], was queried for each of the selected epitopes and ICS peptides. Using 
the home page search tool (http://www.iedb.org/), the database was queried for available 
data on experiments for MHC binding and elution (MHC Ligand assays), and T-cell 
response performed on epitopes/peptides that exactly match the query sequences or 
harbor those sequences as substrings. For the HLA class II ICS search, peptides that are 
70-90% identical to the constructed ICS peptides were also included in the search criteria. 
Before querying the database, the immune recognition context parameters were restricted 
to MHC class I or II-restricted matches (depending on the queried epitope), and Homo 
sapiens (id:9606) selected as the host organism for T-cell assay searches. 
 
4.5 HLA Class II in vitro Binding Assay 
 As a pilot in vitro validation of the predictions performed by the iVAX toolkit, 4 
MHC class II ICS peptides (table 10) were assessed for binding to 4 different purified, 
soluble HLA class II DR alleles (molecules), namely DRB1*01:01, DRB1*04:01, 
DRB1*07:01, and DRB1*15:01 in a competition binding assay against biotinylated 
standards. The presence/absence and strength of peptide binding to a given HLA 
molecule are determined via determining the concentration of test peptide required to 
prevent 50% of standard peptide from binding to the assayed HLA molecule (IC50).    
 The overall strategy of the experiment involved each ICS peptide undergoing the 
assay for each HLA allele in triplicates of 6 dilutions of the peptide in four 96-well 
reaction plates, one plate for each HLA allele. For each reaction plate, positive and 
negative control reactions were performed in triplicates. The positive control reactions 
involved the reaction of HLA allele-specific standard peptides with their respective HLA 
molecules, giving a “maximum fluorescence” reading for the binding of the standard 
peptide. The negative control reactions involved the addition of only the HLA molecules 
to the reaction plates without the addition of any peptides.  
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 At first, lyophilized pellets of the test ICS peptides (21
st
 Century Biochemicals, 
MA, USA) were solubilized in amounts of Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich, 
MO, USA) pre-determined by the manufacturer to obtain a final concentration of 100 μM 
of each peptide. After solubilizing the test peptides, 30 mL of reaction Master Mix were 
prepared by mixing 30 mL of Citrate-phosphate buffer pH 5.4 (prepared by mixing 278 
mL of 2M Sodium phosphate and and 222 mL of 1M Citric acid (Sigma-Aldrich, MO, 
USA)), 300 μL of 1 mM PefaBloc (Roche Applied Science, Penzberg, Germany) and 
225mg of Octyl-β-D-Glucopyranaside (OG) (MP Biomedicals, OH, USA). After 
preparing the master mix, 6 dilutions of the 4 ICS peptides in the master mix were 
prepared in a tube rack composed of 6-rows x 4-columns, where each column was 
designated for one of the 4 ICS peptides. 800μL of master mix solution were transferred 
to all the rows of the tube rack except for the top row, which received 1170μL of 
solution. To each of the 4 tubes in the top row, 46.8μL of the solubilized ICS peptide 
solutions was added, one peptide for each tube. After that, 370.4μL of the master mix-
ICS peptide mixtures in the top row were serially transferred across the remaining 5 
rows, diluting the ICS peptide-master mix solution by a factor of 3.16 across the tubes. 
The dilution factor was predetermined and pre-optimized by EpiVax Inc., and excess 
amounts of master mix and peptide solutions were added to the tube rack based on 
calculations performed according to a project work-plan provided by EpiVax Inc. The 
final dilutions of each peptide in each of the reaction plates across the top 6 rows were:  
100 μmol/mL, 31.6 μmol/mL, 10 μmol/mL, 3.16 μmol/mL, 1 μmol/mL, and 0.316 
μmol/mL.   
 After preparing the ICS dilutions, triplicates of 25μL of each dilution of each 
peptide were transferred to the top 6 rows of four 96-well reaction plates (Fisherbrand, 
Loughborough, UK). 25μL of master mix alone were transferred to the first six wells of 
the bottom row of the four reaction plates where the positive and negative control 
reactions were carried out. To prepare the HLA molecules required for performing the 
binding reactions, purified HLA-DRB1 monomers of the molecules of interest (Benaroya 
Research Institute, WA, USA) were each diluted in 3mL of the prepared master-mix 
based on calculations performed according to the project work-plan provided by EpiVax 
Inc. The exact amounts of monomers diluted were: 0.5μL of DRB1*01:01 monomers 
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from a stock solution with a concentration of 2.5mg/mL, 0.92μL of DRB1*04:01 
monomers from a stock solution with a concentration of 1.3mg/mL, 0.8μL of 
DRB1*07:01 monomers from a stock solution with a concentration of 1.5mg/mL, and 
0.67μL of DRB1*15:01 monomers from a stock solution with a concentration of 
1.8mg/mL. After mixing the aforementioned amounts with 3mL of master-mix each, 
25μL of each diluted monomer solution were directly added to its respective negative 
control wells of the prepared reaction plates, causing the final reaction volume in those 
plates to be 50μL. 
 To prepare the standard biotinylated peptides that will compete with the ICS test 
peptides for HLA binding, aliquots from stock solutions of the standard peptides (21
st
 
Century Biochemicals, MA, USA) were diluted in the prepared HLA monomer-master 
mix mixtures, where each HLA monomer was mixed with a specific standard peptide. 
The standards peptides were diluted in such a way that their final concentrations in the 
wells of the reaction plates became 0.025μmol/mL. Precisely, 6μL from 25μM stock 
solutions of the YAR, Tetanus Toxin, and MBP protein standard peptides were diluted in 
the 3mL solutions of the DRB1-04:01, DRB1-07:01, and DRB1-15:01 monomers 
respectively, and 30μL from a 5μM stock solution of the Influneza A virus Hemaglutinin-
derived standard peptide was diluted in the 3mL solution of the DRB1-01:01 monomer. 
After preparing the biotinylated peptide-HLA mixtures, 25μL of each mixture were 
transferred to the 96-well reaction plates in all the wells containing the test peptides and 
in the positive control wells, causing the total reaction volume in all those cells to be 
50μL. As aforementioned, each reaction plate is only designated for one kind of HLA-
DRB1 allele. After that, the reaction plates were covered and incubated overnight at 37
o
C 
to allow the binding reactions to take place.     
 After putting the reaction plates in incubation, four ELISA plates were prepared 
for capturing the HLA-DR monomers with their bound peptides by coating four 96-well 
EIA/RIA plates (Corning, NY, USA) with L243 anti-HLA-DRA antibodies (BioXCell, 
NH, USA). First, a 1000-fold dilution of the L243 antibodies in Borate buffer pH 8.2 
(prepared by dissolving 1.19g of Sodium tetraborate decahydrate (Sigma-Aldrich, MO, 
USA) in 250mL MilliQ water) was prepared from an antibody stock solution of 
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concentration 10.36mg/mL. Then, 100μL of the prepared antibody solution was 
transferred to each well of the four ELISA plates, and the plates were covered and 
incubated overnight at 4
o
C.  
 On the following day after incubation, the contents of the ELISA plates were 
discarded, and the plates were washed three times with Phosphate Buffer Saline PBS-
0.05% Tween 20 (prepared by mixing 500mL of 10x Dulbecco’s PBS (Life 
Technologies, CA, USA) with 2.5mL of Tween 20 (Sigma-Aldrich, MO, USA) in 4.5L 
of MilliQ water) using an automated plate washer. 40μL of 50mM Tris Neutralization 
buffer (prepared by diluting 1.5mL of 1M Trizma HCL (Sigma-Aldrich, MO, USA) in 
28.5mL of MilliQ water) were then added to each well of the ELISA plates. After that, 
40μL of HLA monomer-peptide reaction mixtures from each well of the overnight 
incubated reaction plates were transferred to their corresponding wells in the ELISA 
plates containing the neutralization buffer. The ELISA plates were then incubated at 37
o
C 
for 2.5 hours.  
 After the 2.5 hour incubation, the contents of the ELISA plates were discarded, 
and the plates were washed three times with PBS-0.05% Tween 20 using an automated 
plate washer. A 1000-fold diluted solution of Streptavidin-Europium in Assay buffer was 
then prepared, where 10μL of Europium-labeled Streptavidin (Perkin-Elmer, MA, USA) 
were diluted in 10mL of DELFIA Assay buffer (Perkin-Elmer, MA, USA). 100μL of 
diluted Streptavidin-Europium solution were then transferred to each well of the ELISA 
plates harboring captured HLA molecules. The plates were then covered and placed in 
the dark for 1 hour at room temperature. After that, the contents of the plates were 
discarded, and the plates were washed three times with PBS-0.05% Tween 20 using an 
automated plate washer, followed by 2 washes with PBS alone to remove any bubbles. 
After that, 100μL of Delfia Enhancement buffer (Perkin-Elmer, MA, USA) were added to 
each well of the ELISA plates, and the plates were again covered and placed in the dark 
for 10 minutes at room temperature. 
 After that, the plates were inserted into a Victor
3
V Microtiter Plate Reader 
(Perkin-Elmer, MA, USA), and the fluorescence of Europium was read under the 
Europium setting. The resultant raw data file was exported in Excel format and stored for 
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IC50 calculations, which were performed using the SigmaPlot 11.1 software package 
(Systat Software Inc., IL, USA) via constructing four parameter logistic curves. 
 
4.6 Conservation Analysis in newly partially re-sequenced HCV 
genomes from the Egyptian Population 
 In an attempt to assess whether the predicted T-cell epitopes are conserved in the 
HCV strains currently circulating in the Egyptian population, a pilot conservation 
analysis has been performed on a group of selected epitopes in partially re-sequenced 
HCV genomes newly isolated from the Egyptian population; epitopes found to be highly 
conserved are, as aforementioned, good candidates for population-specific vaccine 
development.  Specifically, the Core, NS3, NS4B, and NS5B regions of the HCV genome 
-the regions harboring most of the identified epitopes as explained in the results section- 
were targeted for re-sequencing and conservation analysis.  The steps of a protocol 
outlined in Yao et al. (2005) [96] were followed for the Reverse Transcription 
Polymerase Chain Reaction amplification (RT-PCR) and nested PCR amplification of the 
target sequences. The amplification step was followed by Sanger sequencing of the 
amplified sequences and the in silico conservation analysis of the identified epitopes that 
they harbor/cover.     
 
4.6.1 Primer Design: 
 At first, oligonucleotide sense and antisense primers were designed de novo to be 
used in the RT-PCR amplification and Sanger sequencing of the target regions. Since the 
optimal DNA target read length for Sanger sequencing is 700-900 bp long [97], the NS3 
(1893 bp long) and NS5B (1776 bp long) regions were accordingly each divided into two 
frames overlapping by ~140 bp for amplification and sequencing; the Core (573 bp) and 
NS4B (783 bp) regions, however, were targeted for sequencing in single frames, making 
the total number of target HCV RNA frames to be amplified and sequenced 6 out of each 
isolated HCV genome. To design the primers, the 46 HCV-4 sequences retrieved for 
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epitope prediction (table 3) were aligned by multiple sequence alignment using the 
Clustal Omega online tool (http://www.ebi.ac.uk/Tools/msa/clustalo/) [98]; the resultant 
multiple alignment file was then viewed using the ClustalX 2.1 program [99] to allow for 
the visual identification of the most highly conserved RNA sequences flanking the 6 
target regions to be analyzed in order to be used for primer design. Candidate sequences 
were then analyzed using the freely available online OligoAnalyzer 3.1 tool 
(http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/) (Integrated DNA 
Technologies Inc.) with regards to melting and annealing temperatures (Tm and Ta 
respectively), Guanosine and Cytosine percentage (GC content), and the formation of 
hair-pin structures, self-dimers, and heterodimers between sense and antisense primers.  
 To the best extent possible, all primers were designed to have: (1) a GC content of 
40%-60%, which would decrease the likelihood of non-specific priming caused by the 
strong bonding between G and C nucleotides, (2) a maximum negative Gibbs free energy 
(ΔG) value of -3 kcal/mol associated with intra-molecular hairpin structure formation and 
-6 kcal/mol associated with inter-molecular homo and heterodimer structure formation 
between primers; larger negative values for ΔG associated with these structures may 
facilitate their formation at the primer annealing temperatures and consequently decrease 
the availability of these primers for use in the amplification reaction, eventually leading 
to a lower product yield, and (3) a difference in annealing temperature between sense and 
anti-sense primers of not more than 5 degrees [100]. Where possible, nested primers were 
designed in order to carry out nested PCR reactions using the amplicon products of the 
RT-PCR reactions; this would increase the yield and specificity of the amplification 
reactions. Following their design, the primers were ordered for synthesis (Bioneer Inc., 
Daejeon, Republic of Korea). A list of the primer sequences and information about their 
sizes, locations, melting temperatures, and amplicon sizes are listed in table 4. An 
example of the alignment of one of the primers with the 46 HCV-4 sequences is 
illustrated in figure 15. 
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4.6.2 Sample Collection: 
 Left-over anonymous serum samples positive for HCV RNA isolated from the 
Egyptian population were obtained from the sample archives of private diagnostic labs 
collaborating with our research group “Novel Diagnostics and Therapeutics” for HCV 
RNA extraction after obtaining the approval of the Internal Review Board of the 
American University in Cairo. 
 
4.6.3 HCV RNA Extraction:    
 Viral RNA was extracted using the QIAamp® Viral RNA Mini kit (Qiagen, 
Limburg, Netherlands) according to the manufacturer’s “spin column” extraction 
protocol. First, 140 μL of each sample were incubated for 10 minutes at room 
temperature with 560 μL of buffer AVL mixed with 5.6 μL of carrier RNA – AVE buffer 
solution (1 μg/μL). Buffer AVL contains guanidine thiocyanate for lysis of the viral 
particles and denaturation of RNases in the serum sample. The carrier RNA binds to the 
extracted viral RNA, enhancing its subsequent binding to the silica-gel membrane of the 
spin extraction columns and protecting it from degradation by RNases in the unlikely 
event that these RNases escape denaturation by buffer AVL. Before mixing with buffer 
AVL, carrier RNA was first dissolved in buffer AVE, which is RNase-free water 
containing 0.04% sodium azide as a preservative for microbial growth prevention. 
Following the 10 minutes incubation, 560 μL of absolute ethanol were added to each 
sample-AVL-carrier RNA mixture. After that, 630 μL of each mixture were transferred to 
spin columns fitted inside empty collection tubes. The spin columns were then 
centrifuged for 1 minute at 8000 rotations per minute (r.p.m.) at room temperature using 
a 2-16PK centrifuge (Sigma, Osterode, Germany); this step was repeated a second time 
with the remaining 630 μL of sample mixture. Collection tubes containing the filtrate 
were discarded, and the spin columns were placed in new collection tubes.  
 In the following step, 500 μL of AW1 wash buffer were added to each spin 
column, followed by a 1 minute centrifugation at 8000 r.p.m. at room temperature. The 
filtrate was then discarded and a new collection tube was added. 500 μL of AW2 wash 
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buffer were then added to each spin column, followed by a 3 minute centrifugation at 
14,000 r.p.m. at room temperature. The wash buffers purify the viral RNA in the sample 
from other contaminants. After discarding the collection tubes with the filtrate from the 
last centrifugation, the spin columns were then placed in 1.5 mL microcentrifuge tubes 
and 60 μL of nuclease-free water were added to the columns. After one minute incubation 
at room temperature, the spin columns were centrifuged for 1 minute at 8000 rpm at room 
temperature, and the eluate containing the extracted and purified viral HCV RNA was 
retained.  
 
4.6.4 Amplification by RT-PCR: 
  Following HCV RNA extraction, the target Core, NS3, NS4B, and NS5B regions 
were amplified by RT-PCR using the Access RT-PCR System (Promega, WI, USA) and 
the set of external primers (not nested) listed in table 4. Six reaction mixtures for each 
sample, 25 μL each, were prepared for the amplification of the target regions. To prepare 
the reaction mixtures, the following components were added to 0.5 mL PCR tubes: (1) 5 
μL of AMV/Tfl Reaction Buffer (5X), (2) 0.5 μL of dideoxy-nucleotide triphosphate 
(dNTP) mixture (10mM of each nucleotide), (3) 1 μL of Magnesium Sulfate (MgSO4) 
solution (25mM), (4) 2.5 μL of each forward and reverse primers (10 pmol/μL), (5) 0.5 
μL of Avian Myeloblastosis Virus Reverse Transcriptase (AMV RT) (5u/μL), (6) 0.5 μL 
of thermostable Thermus flavus (Tfl) DNA polymerase (5u/μL), (7) 10 μL of extracted 
HCV RNA sample, and (8) nuclease-free water up to 25 μL. Positive control reactions 
were prepared by adding the same components to the reaction tubes with the exception of 
adding of 2 μL positive control RNA with carrier (1 × 106 copies) and 3.3 μL of control 
upstream and downstream primers (50 pmols) provided with the kit instead of the HCV 
RNA template and the de novo designed primers respectively. For negative control 
reactions, nuclease free water was used instead of the positive control RNA with carrier; 
the control upstream and downstream primers were also used for the negative reactions. 
  After preparing the reaction mixtures, the PCR tubes were placed into the Veriti 
90-well Thermal Cycler (Applied Biosystems, CA, USA). The PCR cycling profile was 
set to start with one cycle for first strand (cDNA) synthesis by reverse transcription at 
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45
o
C for 45 minutes, followed by one cycle for the denaturation of the AMV RT at 94
o
C 
for 2 minutes. After that, the samples were subjected to 45 cycles of PCR amplificat ion 
which consisted of: (1) a 30 second template denaturation step at 94
o
C, (2) a 1 minute 
primer annealing step at the optimized temperature of 45
o
C, (3) a 2 minute new stand 
extension step at 68
o
C. A final extension step at 68
o
C was performed for 7 minutes to 
allow the extension of truncated products and enhance the quality of the results. 
  
4.6.5 Nested PCR:       
 To increase the specificity and yield of the amplification reactions, nested PCR 
was performed using the internal nested PCR primers from table 4 and amplicons 
obtained from the RT-PCR step as a template. Nested PCR was performed using either 
the GoTaq® Colorless Master Mix (Promega, WI, USA) kit or the Maxima Hot Start 
PCR Master Mix (Thermo Scientific, MA, USA). To prepare the reaction mixtures, the 
following components were added to 0.5 mL PCR tubes: (1) 25 μL Master mix 
containing a Taq DNA polymerase, (2) 2 μL of each of the forward and reverse primers, 
(3) 10 μL of the RT-PCR amplicon products as templates, and (4) nuclease free water up 
to 50 μL. 
 After preparing the reaction mixtures, the PCR tubes were placed into the Veriti 
90-well Thermal Cycler (Applied Biosystems, CA, USA). The PCR cycling profile was 
set to start with one denaturation step at 95
o
C for 2 minutes, followed by 35 cycles of: (1) 
a 30 second denaturation step at 95
o
C, (2) a 1 minute primer annealing step at optimized 
annealing temperatures for each primer pair, and (3) a 45 second DNA strand extension 
step at 72
o
C. A final extension step for 5 minutes at 72
o
C was performed before stopping 
the reaction. The optimized annealing temperatures that gave the best results for each 
primer pair were: (1) 45
o
C for the AF and ARN pair, (2) 47
o
C for the DF and DRN pair, and 
(3) 50
o
C for the pairs BFN and BR, CFN and CRN, and EF and ERN. No optimized annealing 
temperature was determined for the primer pair FF and FR since amplification reactions 
utilizing this pair did not yield any results by RT-PCR (as will be explained in the results 
section). 
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 The results of the amplification were analyzed by gel electrophoresis on a 1% 
agarose gel. The gel was prepared by dissolving 2g of Seakem® LE Agarose (Lonza, 
Basel, Switzerland) and 6 μL of Ethidium Bromide solution (10mg/mL) (Promega, WI, 
USA) in 200 mL of 1X Tris-Borate-EDTA buffer (Lonza, Basel, Switzerland) and then 
allowing the mixture to solidify. After gel solidification, 5 μL of a 100 bp DNA Ladder 
(Promega, WI, USA) mixed with 2 μL loading dye (provided with the ladder) were 
loaded into the first well. 5 μL of each of the samples’ amplicons were added to the other 
wells mixed with 2 μL loading dye. The gel was then run at 95V for 1 hour in 1X TBE 
running buffer. The amplicon bands were then visualized on an ECX-20.M 
transilluminator (Vilber Lourmat, Marne-la-Vallée, France); images of the gel were taken 
using a Samsung S2 8.0 megapixel mobile phone camera (Samsung, Seoul, South Korea). 
The remainder of the sample amplicons was stored at -20
o
C to be later sequenced.                 
 
4.6.6  PCR Purification and Sanger Sequencing: 
  Purification of the PCR sample amplicons was performed at Sigma Scientific 
Services Co. (Cairo, Egypt) using the GeneJET™ PCR Purification Kit (Thermo 
Scientific, MA, USA) according to the manufacturer’s instructions; where required, gel 
extraction of the amplicons was performed using the same purification kit. Sanger 
sequencing of the purified samples was performed at GATC Biotech AG (Constance, 
Germany) using an ABI 3730xl DNA Analyzer (Applied Biosystems, CA, USA); 
sequencing was performed using the forward and reverse primers for each sample.   
 
4.6.7 Conservation Analysis: 
  After the results of the Sanger sequencing were retrieved, the sequencing 
chromatograms were viewed using the BioEdit sequence alignment editor (Ibis 
Biosciences, CA, USA). Base calls made based on broad peaks or regions with strong 
background “noise” at the 5’ and 3’ ends of the sequences in the chromatogram were 
truncated from the nucleotide sequences. The truncated sequences were then analyzed 
using the Basic Local Alignment Search Tool (BLAST) of the National Center for 
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Biotechnology Information website (NCBI) (http://blast.ncbi.nlm.nih.gov/Blast.cgi); 
where the blastn and blastx programs were used in their default settings to confirm the 
identities of the new sequences. Once confirmed, consensus amino acid sequences of the 
re-sequence regions were assembled by aligning the forward and reverse sequenced 
frames of each region using the Clustal X 2.1 software. Following sequence assembly, 
the conservation of the epitopes across the consensus sequences that cover the locations 
of those epitopes on the HCV-1a (H77) sequence was assessed using the Epitope 
Conservancy Analysis tool of the Immune Epitope Database (IEDB) Analysis Resource 
website (http://tools.immuneepitope.org/tools/conservancy/iedb_input). 
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5. RESULTS 
 
5.1 HLA Class I Epitope Identification and Validation 
 
5.1.1 iVAX analysis results: 
 The Conservatrix and EpiMatrix tools parsed and scored a total of 32,286 9-mer 
peptide frames from the 46 polyprotein sequences. From those, 151 peptides that are fully 
conserved in at least 42 out of the 46 sequences (90% conservancy) and that have a Z-
score ≥ 1.64 were chosen for further analysis; peptides with Z-scores ≥ 1.64 for a given 
allele are most likely to be binders of that allele. The JanusMatrix analysis revealed that 
90 out of the 151 selected epitopes have no cross-reactive hits in the human genome. The 
remaining 61 epitopes do have cross-reactive epitopes ranging from 1 to 9. Accordingly, 
the 90 epitopes with no cross-reactive hits were selected as good putative candidates for 
epitope-driven vaccine design against HCV-4. 
 Analysis of the locations of the 90 epitopes revealed that 23 epitopes are located 
in the Core region, 21 in the NS3 region, 14 in the NS4B region, 15 in the NS5B region, 
5 in the NS5A region, 4 in the E2 region, 2 in the NS2 region, and 1 in the E1 region. No 
epitopes were found to be located in the p7 and NS4A regions. The 5 remaining epitopes 
were found to be located at the junctions between the sequences of non-structural 
proteins. An example of the results of the binding predictions for 7 of the 90 selected 
peptides and their percent conservation and locations in the HCV-4 genome are listed in 
table 5. 
 
5.1.2 Retrospective Validation Results: 
 The IEDB search revealed that 20 out of the 90 selected 9-mer epitopes have no entries 
for previously performed tests for MHC binding, cell-surface presentation, nor the ability to 
elicit a CD8
+
 immune response in previous literature; indicating that those epitopes may 
be novel and have not been previously characterized. As for the remaining 70 epitopes, 
entries have been found for previously performed tests for HLA binding in vitro and/or the 
ability to elicit a CD8
+
 T-cell immune response via in vitro T-cell assays. No entries for 
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MHC elution assays were found for any of the queried epitopes. The 70 epitopes can be 
divided into three categories based on the IEDB results: (1) a category of 20 epitopes that 
tested positive in HLA binding and/or CD8
+
 T-cell assays as 9-mer peptides (exact match 
to the identified sequences), (2) a category of 22 epitopes that tested positive in HLA 
binding and/or CD8
+ 
T- cell assays as substrings of longer peptides, and (3) a category of 
28 epitopes that only tested negative in HLA binding and/or T-cell assays as 9-mer 
peptides and/or as substrings of longer peptides. 
 From the first category of 20 epitopes that tested “positive” for HLA binding 
and/or the ability to trigger a CD8
+
 T-cell response in assays where the 9-mer epitope 
itself has been used as the test peptide or has been empirically identified as the optimal 
epitope causing the positive response from within a larger tested peptide, 9 epitopes were 
previously tested for both HLA binding and the ability to trigger a CD8
+
 T-cell response, 
4 were tested for HLA binding only, and 7 were tested for the ability to trigger a CD8
+
 T-
cell response only. For all the assays performed on the 20 epitopes, the HLA restricting 
allele was determined and listed in the epitopes’ IEDB entries. The results of the HLA 
binding assays performed in previous literature on 4 of the epitopes listed in table 5 are 
listed in table 6 as an example of the returned search results.  In table 7, the results of the 
IEDB search for previously performed T-cell assays also on 4 of the epitopes listed in 
table 5 are displayed; only the entries where the epitope was tested as a 9-mer in previous 
literature are listed.  
 The last column to the right of table 7 describes the methods by which the authors 
of the listed references demonstrated the HLA allelic restrictions of the test epitopes; the 
methods in the table are represented as one number and one letter whose meanings are 
described in table 8. Each number represents a “method” by which the HLA allelic 
restriction has been demonstrated, and each letter represents the basis upon which the 
authors have predicted/known the tested epitopes to be restricted by the listed alleles 
prior to the execution of the assays. The methods of demonstration of HLA restriction 
can be categorized into three methods: the first method involves the use of different lines 
of antigen presenting cells or target cells that bear matching and mismatching sets of 
HLA alleles to the assayed CD8
+
 T-cells from individual(s) carrying a certain HLA allele 
57 
 
X (HLA-X+); if the cells are stimulated by APCs or target cells carrying the same X 
allele but not by ones lacking it, this confirms the restriction of the test epitope by that 
allele. The second method involves the use of HLA tetramers or APCs expressing only a 
single HLA allele (e.g. murine cells expressing a human HLA allele) to trigger the T-cell 
response; if the response is positive, this confirms the restriction of the test epitope by the 
single allele type present in the assay. The third method involves the use of only APCs 
with HLA alleles matching those of the assayed T-cells (usually autologous) to trigger a 
T-cell response; while this method is not sufficient to demonstrate HLA restriction, its 
repetition in more than one assay by more than one author using different patient cohorts 
and different testing methods increases the likelihood of the claimed HLA restriction 
being true. In addition to the methods of demonstration of restriction, authors of the listed 
assays usually have reasons to predict/know the HLA restriction of the epitope prior to 
performing the assay; these include in silico binding predictions, the presence of the HLA 
binding motif in the epitope, an in vitro HLA binding assay, a previous citation 
mentioning/demonstrating HLA restriction, or a combination thereof. Where the reason 
for prediction/knowledge is not listed in table 7, it means that the reason has not been 
clearly mentioned, or that the assay was performed on pools of peptide epitopes that have 
not been previously characterized.   
 For 11 out of the 16 epitopes that tested positive in T-cell assays as 9-mer 
peptides, the listed HLA restrictions were demonstrated at least once by methods “1” 
and/or “2” in previous literature, in addition to the demonstration of some of those 
restrictions by in vitro HLA binding assays. As for the 5 remaining epitopes, the listed 
HLA restrictions were demonstrated only by method “3” in previous literature, which on 
its own is not sufficient to empirically demonstrate HLA restriction. However, for two of 
those epitopes the listed HLA restrictions were empirically demonstrated prior to 
performing the T-cell assays via in vitro binding assays; which in itself can validate the 
EpiMatrix binding predictions. As for the 3 other epitopes, the listed HLA restrictions 
were predicted prior to performing the T-cell assays due to the presence of their binding 
motifs within those epitopes; accordingly, further empirical demonstration of HLA 
restriction for those epitopes is required. 
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 When the results of the EpiMatrix binding predictions for the aforementioned 20 
epitopes were compared to their empirically demonstrated HLA allelic restrictions, it was 
observed that the EpiMatrix predictions for 18 out of 20 of those epitopes were 
retrospectively validated by the empirical results. This is because the HLA alleles that 
were empirically demonstrated to restrict those epitopes had Z-scores ≥1.64, or belonged 
to the same supertypes of the alleles that scored ≥1.64 in the EpiMatrix predictions. 
Furthermore, the HLA allele A*24:02 which was empirically proven to restrict the 
epitope ITYSTYGKF had an EpiMatrix Z-score of 1.4, which although is not ≥1.64 
predicts that the epitope is from amongst the top 10% binders of the allele from within a 
random set of peptides. Accordingly, it can be said that the EpiMatrix predictions 
performed in this analysis were retrospectively validated for 19 out of the 20 epitopes that 
have been positively tested as 9-mers for HLA binding and/or the ability to trigger a 
CD8
+
 T-cell response in human subjects. As for the epitope QYLAGLSTL which was 
empirically demonstrated to bind to the allele A*02:01, the empirical results did not 
validate the EpiMatrix prediction, where the allele was given a Z-score of 0.95. However, 
the binding of that epitope to its highest scoring allele, A*24:02 (Z-score = 2.73), was not 
tested in vitro; empirical validation of binding to this allele is still required. These results 
also take into account the 3 epitopes whose HLA restrictions require further 
confirmation; however their reported allelic restrictions do validate the EpiMatrix results. 
The retrospective validation results of 7 of the 20 epitopes are listed in table 9 as an 
example; these are the same epitopes whose EpiMatrix results are listed in table 5. 
 Apart from the positive entries found on IEDB for the 20 selected epitopes that 
were tested as 9-mers, negative results were also found for HLA binding assays and/or 
CD8
+
 T-cell assays that contradict with the EpiMatrix predictions. With regard to HLA 
binding assays, 4 epitopes were shown to be negative binders of HLA class I alleles 
where the negative results contradict with their EpiMatrix scores; despite the fact that all 
4 epitopes possess the binding motifs of the supertypes to which those alleles belong. 
With regard to CD8
+
 T-cell assays, entries with “Negative” results for 15 out of the 20 
epitopes were found, where the negative result was attributed to the 9-mer itself. For 9 
out of those 15 epitopes, the restricting HLA allele associated with the negative response 
was determined, and the negative results contradicted with the EpiMatrix binding 
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predictions. However, due to the widely varying responses between patient cohorts and 
different experimental setups, these negative results cannot be used to rule out those 
epitopes from further analysis; further standardized testing is required to draw a final 
conclusion. 
 In addition to the 20 epitopes that have been tested positive as 9-mers, the IEDB 
search revealed that 22 out of the 70 chosen epitopes (category 2) had positive entries for 
HLA binding and/or the ability to trigger a CD8
+
 T-cell response as substrings of 10-mer 
and/or multimer peptides (>10 AA). HLA binding assay results for these peptides cannot 
be used for the validation of the EpiMatrix predictions since they represent the binding 
affinities of the 10mer and multimer peptides themselves, and accordingly will not be 
considered. Only the results of T-cell assays will be considered, since multimer peptides 
undergo processing before presentation on MHC class I molecules. However, since the 
optimal epitope size for HLA class I molecules is 9 to 11 AA, the results where the 
peptides were tested as 10-mers or where the optimal/minimal epitope has been identified 
as a 10-mer are less likely to be attributed to the 9-mer peptide frames harbored within 
them as substrings, and hence will not be used as evidence for validation of the EpiMatrix 
results. Of the 22 epitopes mentioned herein, only 9 tested positive for the ability to 
trigger a CD8
+
 T-cell response as multimers and had the restricting HLA allele 
determined. These results warrant support for further investigation via truncation analysis 
in order to identify the optimal/minimal epitope causing the positive response or maximal 
stimulation of the CD8
+
 T-cells. Since in this project only 9-mer binding predictions have 
been performed, it is not possible to predict which 9-mer, 10-mer, or 11-mer frame is 
responsible for the optimal positive response from within the multimer peptide. The 
IEDB search for the remaining 28 of the 70 epitopes (category 3) to which entries were 
found in IEDB returned only negative results, which, as aforementioned, cannot be used 
to rule out those epitopes from further analysis.   
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5.2 HLA Class II Epitope Identification and Validation 
 
5.2.1 iVAX analysis results: 
 From the 32,286 peptide frames scored by Conservatrix and EpiMatrix for 
conservation across the 46 genomes and for binding to the aforementioned DRB1 alleles 
respectively, the EpiAssembler tool selected 156 9-mer peptide frames to construct 14 
extended ICS peptides, which harbor 9-mer frames in their core sequence that are 
collectively conserved in >90% of the analyzed sequences (Open Reading Frame ORF 
coverage >90%) and which have a minimum EpiMatrix cluster immunogenicity score of 
10. Table 10 lists the results of the EpiAssembler analysis for 5 of the 14 ICS peptides. 
The EpiMatrix Z-scores assigned for each of the component 9-mer frames of one ICS 
peptide for binding to the analyzed HLA-DRB1 alleles and their percent conservation 
calculated by Conservatrix are listed in table 11 as an example. Peptide frames with 4 or 
more “hits” are referred to as “EpiBars” and are therefore promiscuous binders. All of the 
14 constructed ICS peptides harbor at least one EpiBar.  
Analysis of the locations of the ICS peptides revealed that 8 lie in the NS4B 
region, 3 in the NS5B region, 1 in the Core region, 1 in the NS3 region, and 1 at the 
junction between the NS2 and NS3 protein sequences. JanusMatrix analysis showed that 
all of the 14 ICS peptides possess a certain degree of homology to the human genome as 
demonstrated by their JanusMatrix cluster scores (table 10). JanusMatrix cluster scores 
are equal to the EpiMatrix cluster immunogenicity scores minus penalty deductions for 
each cross-reactive match in the human genome for each of the 9-mer component 
peptides of the ICS core sequence. The larger the difference between both cluster scores 
(EpiMatrix and JanusMatrix), the higher the homology to the human genome. Therefore, 
ICS peptides having a smaller difference between both scores are considered better 
candidates for inclusion in the final vaccine. Further empirical testing, however, is 
required to assess the efficacy and safety of the ICS peptides before deciding on which 
ones to include in the final product.  
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5.2.2 Retrospective validation results: 
The IEDB search revealed that none of the 14 peptides have been tested earlier as 
exact sequences, however, all 14 have been previously tested for HLA class II binding 
and/or the ability to trigger a CD4
+
 T-cell response as substring peptides or as peptides 
that are 70-99% similar to the ICS peptides (IEDB BLAST 70%-90% search). Of the 14 
peptides, 8 have been previously shown (as substrings and/or similar sequences) to 
positively bind to different HLA class II alleles via in vitro binding assays; the IEDB 
search results for HLA class II binding assays for 4 of these 8 peptides are listed in table 
12. Only the results for test peptides that include at least one 9-mer frame from the core 
sequence (excluding the 3 AA terminal residues at the N and C termini) of the 
corresponding ICS peptide within their core sequence are listed. All binding assays 
performed were purified MHC competition binding assays.  
With regard to their ability to trigger a CD4
+
 T-cell response, the IEDB search 
revealed that 13 out of the 14 ICS peptides have been previously tested positive in CD4
+
 
T-cell assays (as substrings and/or similar sequences). For only 5 out of the 13, the 
restricting HLA class II allele associated with the positive response has been determined; 
Table 13 lists the results of the IEDB search for 3 of those 5 ICS peptides; only the 
entries where the restricting HLA allele has been determined and where the test peptides 
or the empirically-determined minimal epitopes include at least one 9-mer frame from the 
core sequence of the ICS peptide within their core sequence are listed. In all of the assays 
performed on the 5 ICS peptides, the HLA allelic restriction was determined using 
methods 1 and/or 2 mentioned in table 8. 
Upon comparing the IEDB results of the 8 aforementioned ICS peptides with the 
EpiMatrix predictions, it was found that 39 out of 51 EpiMatrix binding predictions 
performed for the component 9-mer frames of the 8 peptides collectively have been 
validated as true positive (TP) or true negative (TN). However, 12 binding predictions 
had contradicting IEDB results. Further empirical testing must be carried out to confirm 
or refute the EpiMatrix predictions before rendering these predictions as false positives 
(FP); especially that, for most of the 12 predictions, the contradicting results were 
reported in a single corresponding reference. Table 14 lists the results of the retrospective 
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validation performed for the ICS peptide NS31246-1265(SQGYKVLVLNPSVAATLGFG) 
as an example. For each IEDB entry for HLA binding or T-cell assays performed on the 
peptide demonstrated in tables 12 and 13, Table 14 lists whether the HLA restrictions that 
tested positive or negative for peptide binding confirm or refute the EpiMatrix predictions 
for each of the eight analyzed HLA class II alleles. 
Apart from the 8 ICS peptides that have been tested for HLA binding and the 
ability to trigger a T-cell response with the restricting allele determined, the remainder 6 
peptides were all tested for the ability to trigger a CD4
+
 T-cell response in previous 
literature, and 6 of those tested positive, however without the restricting HLA allele being 
determined. These results need to be tested further in the future, and the restricting HLA 
class II alleles driving the response need to be determined. 
 
5.3 HLA Class II in vitro binding assay  
Table 15 displays the results of the pilot HLA class II binding assay compared to 
the highest Z-score calculated by EpiMatrix assigned to one of the core 9-mer frames (the 
frame most likely to bind with high affinity to the binding pockets of the HLA class II 
molecules). All ICS peptides were found generally to bind with high affinity to the tested 
HLA class II molecules, validating the EpiMatrix binding predictions, and confirming the 
results of the retrospective validation. This is true except for the peptide NS4B1769–
1786(VSGIQYLAGLSTLPGNPA), which failed to bind to the allele DRB1*07:01 in 
contradiction to the EpiMatrix pedictions. This negative result was also reported from 
three different references as shown in table 12 [137-139]. This strongly suggests that the 
EpiMatrix binding prediction for this peptide for binding to the DRB1*07:01 allele is a 
false positive. 
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5.4 Conservation Analysis in newly partially re-sequenced HCV 
 genomes from the Egyptian population      
 HCV genomes from 15 serum samples were successfully amplified by RT-PCR; 
however, not all 6 regions were successfully amplified in all the extracted genomes. 
Table 16 shows 25 genomic fragments from the 15 sequences that were successfully 
amplified. The second fragment of NS5B failed to amplify in all serum samples, which 
suggests that the sequences of one or both primers targeting that region may have not 
been correctly synthesized. Examples of electrophoresis gel photos showing the bands 
corresponding to the nested PCR products are shown in figure 16; gel lanes that are not 
labeled belong to regions from the HCV sample regions that failed to amplify. 
 Following amplification, only 23 regions from 14 serum samples were 
successfully sequenced in the forward and/or reverse directions, as shown in table 16. 
Sample regions K9-NS5B(1) and K10-NS3(2) were not successfully sequenced in neither 
the forward nor reverse directions because the amount of DNA amplicons in the samples 
was insufficient for performing the sequencing reactions; this insufficiency was probably 
due to sample loss by acid hydrolysis upon repeated freeze-thaw cycles and/or during the 
purification of the PCR amplicons. Sample region K2-NS5B(1) was successfully 
sequenced in the forward direction only. After examining the resulting sequencing 
chromatograms of the forward and reverse sequencing reactions performed on the 23 
sample regions that were successfully sequenced, it was found that, out of 45 forward and 
reverse sequences (excluding the reverse sequence of K2-NS5B(1)), 38 sequences were 
found to be of high quality, with clear chromatograms that have low background noise 
and distinct sharp peaks for each nucleotide along the sequence (after truncating the low 
quality nucleotide peaks at the 5’ and 3’ ends of the sequences). The chromatograms of 
the remaining 7 sequences were of low quality with a lot of background noise and broad 
peaks along the lengths of the sequences, and accordingly were not carried forward for 
further analysis; these 7 sequences, however, had corresponding sequences of the 
opposite polarity that were of high quality which were used to determine the amino acid 
sequences of the sample regions. The quality of the successfully sequenced samples and 
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their sizes after truncation are listed in table 17. Examples of good quality and bad quality 
chromatograms are displayed in figure 17. 
 The results of the BLAST analysis confirmed the identities of most of the high 
quality truncated sequences; the highest scoring matches belonged to HCV genotype 4, 
with alignment scores > 200 and expect (E) values of 0.0. The BLASTX results of the 
sequence K1-NS3(2)-F showed that the sequence was translated into two reading frames 
located 10 amino acids apart, with alignment scores > 200 for all aligned results; this 
could be due to insertion or deletion mutations that caused a frame shift in the analyzed 
sequence probably inserted during the amplification or sequencing reactions. The 
BLASTN analysis of the sequences K6-NS3(1)-R, K7- NS3(1)-F, and K7- NS3(1)-R did 
not return any results with significant similarity, despite the good quality of the 
chromatograms of the truncated sequences that were analyzed; the sequences of those 
regions, therefore, were not used for the conservation analysis. Furthermore, BLASTN 
analysis of the sequences K8-NS5B(1)-R, K10-NS3(2)-F, and K10-NS3(2)-R showed 
that these sequences had matches with sequences from the human genome, suggesting 
that samples K8 and K10 were contaminated with human RNA carried over from the 
HCV RNA extraction step, which at the low annealing temperatures of the PCR reactions 
may have been non specifically amplified.  
 Following the BLAST analysis, the high quality forward and reverse sequences of 
confirmed identities were assembled to derive the consensus sequences of the 
corresponding regions. If a mismatch was present between the amino acid sequences of 
the forward and reverse fragments, the amino acid residues used for the construction of 
the consensus sequence were those matching the corresponding residues of the highest 
scoring aligned sequences in the BLAST analysis. The locations of the resultant 
consensus amino acid sequences are listed in table 18. 
 The results of the conservation analysis using the Epitope Conservancy Analysis 
tool of the IEDB Analysis Resource website show that, out of 16 HLA class I epitopes in 
the NS3 region covered by the consensus sequences, 14 were 100% conserved across the 
sequences that harbored them, while 2 were only 50% conserved; the only HLA class II 
ICS peptide harbored within that region was also conserved in 100% of the sequences 
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that covered it. With regard to the NS4B region, all 14 HLA class I epitopes that were 
identified by the in silico analysis were 100% conserved across the sequences that 
harbored them, and the same result was reached for 5 HLA class II ICS peptides harbored 
within those sequences. As for the Core region, 21 out of the 23 HLA class I epitopes 
identified in silico were found to be 100% conserved across the sequences that harbored 
them, and only 1 was found to be only 75% conserved; the only ICS class II peptide 
located in the Core region was not covered by the new sequences. As for the NS5B(1) 
region, none of the NS5B epitopes identified in silico within this region (2 epitopes) were 
covered by the new sequences; this is because these epitopes are locate in the 5’ end of 
the new sequences which was truncated due to the low quality of the sequencing 
chromatograms in that region. Most of the identified NS5B epitopes (13 out of 15 HLA 
class I epitopes and 3 HLA class II ICS peptides) are located within the region NS5B(2) 
which failed to amplify in all the obtained serum samples. 
 It is important to note that, as evident from table 17, the number of new sequences 
analyzed for each region is not the same. For example, the two HLA class I epitopes that 
were found to be only 50% conserved in the NS3 region were only covered by 2 new 
NS3 sample region sequences, making them conserved in only 1 of the 2; also, the Core 
HLA class I epitope that was found to be conserved in 75% of the sequences was covered 
by only 4 new sequences, making it conserved in 3 out of the 4. Generally, the maximum 
number of new sequences across which the conservancy of any given epitope was 
analyzed was 5, and the minimum was 2. For a pilot study, the results of this 
conservation analysis add to the results of the analysis performed by the Conservatix tool 
of the iVAX toolkit and confirm the high conservancy of the analyzed epitopes. A larger 
number of new sequences from the Egyptian population are required, however, to draw 
stronger conclusions about the conservancy of the analyzed epitopes in the HCV RNA 
genomes currently circulating in the Egyptian population. If significant deviations from 
the conservation analysis results obtained so far are to be found, this will not only 
possibly alter the decision of which epitopes are to be included in a population-specific 
vaccine for Egypt, but will also indicate the evolution of new HCV strains in the 
population that require investigation. An example of the results of the conservation 
analysis performed on the new sequences is displayed in table 19.                       
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6. DISCUSSION 
 
 In this project, the immunoinformatics-based identification of a group of highly 
conserved and immunogenic T-cell epitopes from the HCV-4 proteome using the 
validated iVAX immunoinformatics toolkit was described, as a first step towards the 
development of an epitope-driven vaccine that targets HCV-4. A retrospective validation 
of the results was also performed using the repository of HCV immune epitope data on 
the IEDB; thereby introducing a fast and inexpensive method for the validation of in 
silico epitope prediction. The results of the retrospective analysis of 4 HLA class II 
constructed ICS peptides were also confirmed by a pilot HLA class II binding assay. 
Furthermore, a pilot conservation analysis of the predicted epitopes in the proteomes of 
HCV strains currently circulating in the Egyptian population was also performed. Based 
on this analysis, a group of 90 HLA class I epitopes and 14 HLA class II ICS peptides 
were identified as good putative candidates for vaccine design. A flowchart summarizing 
the epitopes’ prediction and selection process and their retrospective validation is 
presented in figure 18. 
 Based on the results of the retrospective validation, 20 out of the set of 90 HLA 
class I epitopes were found to have no previous records of empirical testing via HLA 
binding assays nor T-cell assays, which warrants support for future research to 
investigate their roles in the interplay between HCV-4 and the host immune system, and 
to evaluate their efficacy as vaccine targets. From the remaining 70 HLA class I epitopes, 
the EpiMatrix prediction results of 19 out of 20 epitopes were validated; where those 20 
epitopes were previously tested positive in empirical assays where the test peptides were 
the 9-mer epitope sequences themselves. The results of most of the EpiMatrix predictions 
for 8 out 14 HLA class II ICS peptides were also validated by retrospective analysis. 
These results demonstrate the high accuracy of EpiMatrix as an epitope-mapping tool. In 
most of the T-cell assays performed on the class I and II epitopes in previous literature, 
the HCV source genotype of the sequences of the test epitopes and the HCV genotype 
infecting the human test subjects was either genotype 1 or undetermined; genotypes 2 and 
3 were also present as the source or infecting genotypes but to a much lesser extent. This 
indicates that the tested epitopes are conserved in HCV genotypes other than HCV-4, 
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meaning that they lie in locations in the viral proteins that affect the structure and 
function of the protein harboring them and influence the viral life cycle, and hence are 
difficult to mutate.   
 Different kinds of HLA binding assays were performed on the epitopes in 
previous literature, the most frequent of which is the purified MHC binding competition 
assay, where the binding affinity of the test epitope is measured by determining the 
concentration of that epitope required to inhibit the binding of 50% of a labeled standard 
epitope to the same purified MHC allele (Inhibitory Concentration 50 [IC50]) [23]. Cell-
bound MHC assays have also been performed; these include: (1) a competition assay, 
which is similar in concept to the described purified MHC binding competition assay but 
with the HLA allele bound to an experimental cell line and not purified [113], (2) a 
dissociation (complex stability) assay, where the binding affinity of the test epitope is 
measured by determining the time required for it to dissociate from its cell-bound MHC 
allele [112], and (3) association assays, where the affinity of the test epitope is quantified 
by its ability to associate to and stabilize MHC molecules on the surface of experimental 
cell lines compared to controls [105,141-143]. Examples of T-cell assays performed on 
the epitopes in previous literature include: (1) Enzyme-linked immunosorbent (ELISA) 
and Enzyme-linked immunosorbent spot (ELISPOT) assays, which detect T-cell 
responses by measuring cytokine secretion from T-cells (mainly IFN-γ in the IEDB 
results) in response to stimulation by the test epitopes [23], (2) cytotoxicity assays, which 
detect the cytotoxic (lytic) response of CD8
+
 T-cell to target cells displaying the test 
epitope on their surface by measuring the release of a marker, usually the radioisotope 
Chromium 51, from the lysed target cells [105], (3) MHC tetramer staining assays, where 
streptavidin-labeled tetrameric constructs of MHC alleles in association with the test 
epitope are used to detect and quantify the amount of T-cells in a given blood sample that 
are specific for that epitope [144], (4) intracellular cytokine staining (ICS) assays, where 
the T-cell response is measured by detecting cytokines produced intra-cellularly in 
response to stimulation by the test peptide via intra-cellular cytokine staining followed by 
flow cytometry for visualization [23], and (5) proliferation assays, where the T-cell 
response is detected by measuring the proliferation of those T-cells in response to 
stimulation by the test epitope [23]. 
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 When the locations of the identified HLA class I and II epitopes were mapped on 
the HCV polyprotein sequence, it was found that most epitopes are located within the 
Core, NS3, NS4B, and NS5B regions. Within the Core protein region, which is the 
building block of the viral capsid, 23 class I epitopes and one class II ICS peptide were 
identified. Within the NS3 protein region, 21 class I epitopes and one class II ICS peptide 
were identified. Within the NS4B protein region, 14 HLA class I epitopes and 8 HLA 
class II ICS peptides were identified, and finally within the NS5B region, 15 HLA class I 
epitopes and 3 class II ICS peptides were identified. Due to the important structural and 
functional roles that these proteins play in the HCV life cycle, it is difficult for the virus 
to mutate those sequences at low fitness costs, which explains why the biggest proportion 
of the conserved epitopes identified in this project was located within those regions. 
Furthermore, a large group of those epitopes was also found to be conserved in other 
HCV genotypes, as demonstrated by the retrospective validation results performed on 
IEDB. This does not only demonstrate the importance of those epitopes’ sequences in the 
HCV life cycle, but also means that these epitopes provide excellent targets for a cross-
genotype effective vaccine. On the other hand, in the E1 and E2 regions, very few highly 
conserved epitopes were identified relative to the sizes of those regions, which is 
explained by the hypervariable nature of those proteins required for the virus to escape 
recognition from the humoral immune system. 
 In order to avoid triggering a suppressive or autoimmune response to the final 
vaccine product, the novel JanusMatrix tool was used to assess the homology of the 
analyzed epitope set to the human genome; epitopes with several cross-reactive hits with 
epitopes derived from the human genome are better to be excluded from the final 
product. In this project, a highly stringent selection of HLA class I epitopes that had 0 
cross-reactive hits in the human genome was performed. The same could not be done for 
the HLA class II ICS peptides, which all had some degree of homology to the human 
genome; if 9-mer peptide frames within the ICS peptides were to be removed to decrease 
this degree of homology, the promiscuous coverage of the HLA-DR alleles provided by 
the peptides, their ability to bind to HLA class II molecules, and their HCV-4 subtype 
coverage would all be compromised. Here it is important to note that when a large set of 
empirically characterized T-effector cell epitopes were analyzed by JanusMatrix, it was 
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found that a T-cell epitope homologous to the human genome may still be able to 
successfully trigger a T-effector cell response if that degree of homology lies within a 
certain ratio of cross-reactive hits per number of AA residues in the human genome 
database [84]. Therefore, future empirical analysis of the kind of responses the HLA class 
II ICS peptides can trigger is required before deciding on which epitopes to include in the 
vaccine. While JanusMatrix is efficient in identifying homologous epitopes derived from 
the human genome, it cannot identify all of the putatively cross-reactive epitopes. This is 
because, in reality, the TCRs of cross-reactive T-cells can recognize their target epitopes 
by the conformational availability of their AA side-chain residues and not just their exact 
sequence identity. However, JanusMatrix can still provide a preliminary prediction of 
cross-reactivity based on sequence identity that can narrow down the selection of 
epitopes which would be later tested empirically for the nature of the immune response 
that they can trigger [84]. Work is currently still in progress to establish a normalized 
scoring scheme for JanusMatrix (similar to EpiMatrix Z-score) to define a threshold 
based on which the nature of the analyzed epitopes (whether effector or suppressive) can 
be determined. 
 The conservation analysis performed on the newly partially re-sequenced HCV 
genomes isolated from the Egyptian population showed that almost all the epitopes 
located within the new sequences were fully conserved across them. This indicates that 
these epitopes may provide good coverage of the HCV strains currently circulating in the 
Egyptian population, which makes them good candidates for a vaccine that can be 
effective in Egypt; however, the number of sequences included in the analysis is 
relatively small, which decreases the power of the conclusions drawn from the analysis. 
From the small amount of serum samples that could be obtained to carry out the analysis, 
not all regions were successfully amplified; which could be attributed to low viral loads 
in the samples, mismatches between the HCV RNA and the amplification and sequencing 
primers, and/or the degradation of the HCV RNA with repeated freeze-thaw cycles. 
Furthermore, HCV RNA is known to have a relatively high GC content, meaning that 2ry 
RNA structures may have been difficult to denature at the low primer annealing 
temperatures employed in the reactions. All the above factors may have contributed to the 
decrease in availability of enough HCV RNA templates to perform the RT-PCR 
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amplification. This is supported by the fact that, for the sample regions that did amplify, a 
relatively large volume of extracted HCV RNA was required to carry out the reactions at 
low optimal annealing temperatures. Better results can be obtained in the future by 
determining the viral load of the analyzed sequences prior to amplification so as to only 
use samples with high viral loads, and by using  primer sequences that are designed based 
on only the HCV-4 strains derived from the Egyptian population.       
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7. CONCLUSION 
 
 HCV-4 is the predominant HCV genotype in the Middle East and Africa; in 
Egypt, the country with the highest HCV infection rates worldwide, more than 90% of 
the infections are attributed to the same genotype. Despite the direness of the issue, very 
limited attention has been given to HCV-4 as a vaccine target in HCV vaccine research. 
In an attempt to fill this gap in research, this project describes the in silico identification 
and selection of a group of highly conserved and immunogenic T-cell epitopes from the 
HCV-4 proteome as a first step for the development of an epitope-driven vaccine against 
HCV-4. The iVAX immunoinformatics toolkit was used to identify the epitopes; where 
its epitope prediction tool, EpiMatrix, was proven to be of the most accurate epitope 
prediction tools available online. The in silico results were retrospectively validated using 
the repository of empirical HCV immune epitope data on the IEDB; thus demonstrating 
the accuracy of EpiMatrix as a prediction tool, and the conservation of the identified 
epitopes across other HCV genotypes. This retrospective method of validation can 
provide a fast and inexpensive alternative to performing empirical validations from 
scratch for different strains of previously investigated pathogens, such as HCV, HIV, 
Influenza, or Coronaviruses. The method can be useful when designing population-
specific or personalized vaccines and/or in the case of an outbreak caused by a new strain 
of a given pathogen. In addition to identifying and retrospectively validating the epitopes, 
the HCV-4 subtype sequence coverage provided by the identified epitopes for the HCV 
strains circulating in the Egyptian population has been investigated, as a pilot assessment 
of the putative efficacy of the vaccine when used in Egypt. 
 In the future, empirical characterization of the 20 novel HLA class I epitopes 
identified by the iVAX analysis must be carried out, and further assessment of the 
efficacy of the retrospectively validated HLA class I and class II T-cell epitopes as 
vaccine targets in patient populations where HCV-4 prevalence is high needs to be 
pursued. Pre-clinical trials for previously thoroughly investigated epitopes using small 
animal models can be directly undertaken. In the coming years, several new drugs for 
HCV treatment will enter the market, just like the recently approved drug Sofobuvir. 
These drugs, although they hold promise for increasing the rates of treatment success, 
72 
 
remain very expensive for patient populations in the Middle East and Africa. The 
development of an effective vaccine targeting those populations will have a strong impact 
on HCV therapy and prophylaxis. 
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8. TABLES 
 
Table 1: HCV Structural & Non-Structural Proteins and their functions.  A summary of the roles 
that HCV proteins play in the HCV life cycle [12]. 
Protein Function 
Core Forms the viral nucleocapsid. 
E1 & E2 
Mediate viral attachment to cell-surface receptors and fusion of viral and cellular 
membranes in the viral entry step of the HCV life cycle. 
p7 
Cation channel (viroporin), essential for assembly and release of infectious HCV 
particles.  
NS2 
Constitutes the cis-acting auto-protease together with NS3 for cleavage of the NS2-
NS3 junction in the precursor polyprotein molecule. 
NS3 
A multi-functional protein. The N-terminal one-third harbors a serine protease 
catalytic domain that catalyzes cleavage of the polyprotein molecule at the NS2/NS3, 
NS3/NS4A, NS4A/NS4B, NS4B/NS5A, and the NS5A/NS5B junctions with the aid of 
the NS4A co-factor. The C-terminal two-thirds of the protein harbor an RNA 
helicase/NTPase, which is suggested to unwind extensive secondary RNA structures 
during RNA replication.   
NS4A Co-factor of NS3 serine protease activity. 
NS4B 
Induces formation of the membranous web, the site of HCV RNA replication in the 
host cell 
NS5A Modulates the efficiency of viral RNA replication 
NS5B RNA-dependant-RNA polymerase, catalyzes viral RNA replication 
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Table 2: HCV Vaccines in Clinical Trials. Examples of HCV vaccines currently undergoing clinical trials, and the results of these trials as reported 
so far [17]. 
Vaccine Type, Components, 
& Investigator Company 
Source HCV 
genotype 
Phase 
(Year) 
 
Tested subjects Outcome Notes 
Recombinant protein  
E1/E2 protein + MF59C 
adjuvant 
(Novartis Inc.) 
1a I (2010) 60 healthy subjects Safe and elicited antibody 
and T-cell responses in all 
subjects. 
In pre-clinical trials it elicited antibody and T-cell 
responses in 21 chimpanzees: 5 developed sterilizing 
immunity against a homologous challenge with HCV-
1a, and 14 managed to clear the challenge virus after 
infection [57]. 
 
Peptide Vaccine  
IC41: 5 peptides from Core,  
NS3, and NS4 regions  
+ poly-L-arginine adjuvant 
(Intercell AG) 
 
1 and 2 II (2008)  60 patients, 
chronic HCV-1 
infection, HLA-A2 
positive 
Safe, induces T-cell 
response in 67% of 
patients, and caused 
decrease in viremia >1 
log in 3 subjects.  
A new phase II clinical trial for the vaccine has been 
started in 2011 testing the effects of the vaccine in 
combination with the new broad spectrum antiviral 
Nitazoxanide. 
DNA Vaccine 
ChonVac-C: plasmid 
expressing NS3/4a protein 
(Tripep AB) 
 
N/A I/IIa 
(2009) 
12 treatment-
naive patients 
infected with HCV-
1 
Safe, caused >0.5 log 
decrease in viral load in 
4/6 patients who 
received higher doses  
Delivered by electroporation to enhance intramuscular 
injection immunogenicity. 
Vector Vaccine 
TG4040: Modified vaccinia 
Ankara (MVA) vector 
expressing NS3,4, and 5B 
proteins 
(Transgene) 
 
N/A I (2009) 15 patients with 
Chronic HCV 
Caused 0.5–1.4 decline in 
viral load in 6/15 
patients. 
Phase II trial planned in combination with standard 
therapy.  
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Table 3: Analyzed HCV-4 Sequences. A List of the 46 HCV IV full genomes whose corresponding 
polyprotein amino acid sequences were uploaded to the iVAX server for epitope prediction and 
analysis. 
Accession 
Number 
Genotype/Subtype 
RNA 
Sequence 
Length 
Protein ID 
Amino Acid 
Sequence 
Length 
Sampling 
Country 
Reference 
DQ418782 4a 9292 ABD75824 3009 U.S.A. 
 [87] 
DQ418783 4a 9253 ABD75825 3008 U.S.A. 
DQ418784 4a 9298 ABD75826 3008 U.S.A. 
DQ418785 4 9218 ABD75827 2985 U.S.A. 
DQ418786 4d 9273 ABD75828 3007 U.S.A. 
DQ418787 4a 9307 ABD75829 3008 U.S.A. 
DQ418788 4a 9306 ABD75830 3008 U.S.A. 
DQ418789 4a 9295 ABD75831 3008 U.S.A. 
DQ516083 4d 9300 ABF60956 3006 Spain 
 [88] 
DQ516084 4a 9309 ABF60957 3009 Spain 
DQ988073 4a 8957 ABL63005 2899 Egypt 
Direct 
Submission  
DQ988074 4a 9054 ABL63006 2932 Egypt 
DQ988075 4a 9057 ABL63007 2933 Egypt 
DQ988076 4a 9051 ABL63008 2931 Egypt 
DQ988077 4a 9043 ABL63009 2928 Egypt 
DQ988078 4a 9050 ABL63010 2932 Egypt 
DQ988079 4a 8965 ABL63011 2902 Egypt 
EF589160 4f 9181 ABU68271 2969 France 
[89] 
EF589161 4f 9304 ABU68272 3010 France 
EU392169 4f 9309 ACB45490 3009 N/A 
[90] 
EU392170 4f 9269 ACB45491 3009 N/A 
EU392171 4K 9281 ACB45492 3011 N/A 
EU392172 4d 9299 ACB45493 3006 N/A 
EU392173 4k 9312 ACB45494 3011 N/A 
EU392174 4f 9298 ACB45495 3009 N/A 
EU392175 4f 9297 ACB45496 3009 N/A 
FJ025854 4b 9267 ACL68400 3010 Portugal 
[91] FJ025855 4b 9242 ACL68401 3011 Portugal 
FJ025856 4b 9271 ACL68402 3011 Portugal 
FJ462431 4p 9475 ACS29430 3009 Canada 
[20] 
FJ462432 4g 9435 ACS29431 3008 Canada 
FJ462433 4m 9425 ACS29432 3006 Canada 
FJ462434 4q 9433 ACS29433 3010 Canada 
FJ462435 4b 9440 ACS29434 3011 Canada 
FJ462436 4c 9468 ACS29435 3022 Canada 
FJ462437 4d 9421 ACS29436 3006 Canada 
FJ462438 4k 9438 ACS29437 3011 Canada 
FJ462439 4r 9440 ACS29438 3011 Canada 
FJ462440 4o 9422 ACS29439 3005 Canada 
FJ462441 4n 9435 ACS29440 3008 Canada 
FJ839869 4t 9488 ACT66294 3007 Canada 
FJ839870 4l 9388 ACT66295 3006 Canada 
GU814265 4a 9497 ADF97233 3008 Egypt [92] 
HQ537008 4v 9174 AEI00316 2973 Cyprus 
[93] 
HQ537009 4v 9177 AEI00317 2974 Cyprus 
NC_009825 4a 9355 YP_001469632 3008 Egypt [94] 
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Table 4: RT-PCR and Sanger Sequencing primers. The polarity of the primers is denoted in subscript letters (F: Forward, R: Reverse). Nested 
primers are denoted by the subscript letter ‘N’; not all nested primers have a nested counterpart of opposite polarity.   
Forward Primers Reverse Primers Amplicon 
size 
Target Region 
Primer Primer Sequence (5' - 3') Location  Length (nt)  Tm (oC) Primer Primer Sequence (5' - 3') Location  Length  Tm (oC) 
AF TGATAGGGTGCTTGCGAGTGC 294 - 314 21 59.7 
AR TGCTKGAATTCGGGCAGTCRTT 954 - 975 22 62 679 bp 
Core 
ARN CACGAGAGAAGTGCCAARAGGAAGAT 867 - 892 26 60.9 599 bp 
BF YGGCAGGGACACCAAYGA 3485 - 3502 18 56.3 
BR AGGGCGACCTCCTCTATRTT 4422 - 4441 20 53.7 
957 bp 
NS3 (1) 
BFN GTACACCAATGTTGACCARGA  3641 - 3661 21 50.9 801 bp 
CF ATCATCTGTGACGARTGCCA 4278 - 4297 20 53.3 CR GCTGACATACAAGCCATGATGTAYTT 5268 - 5293 26 57.3 1016 bp 
NS3 (2) 
CFN GTCCTGGACCAAGCGGARAC 4335 - 4354 20 56.8 CRN CACTTCCACATGGTGTCCCA 5151 - 5170 20 56 836 bp 
DF CAGTTTGACGAAATGGARGARTG 5451 - 5473 23 56.5 
DR TTTAGCCACGTYTTGAAGTCA  6308 - 6328 21 52.8 878 bp 
NS4B 
DRN GTCTGARAAGGGATGTCACAGT 6195 - 6216 22 50.6 766 bp 
EF TGYTGCTCAATGTCATAYTCATGGAC 7596 - 7621 26 59.8 
ER ACRTAGAGTCTYTCTGTGAGGGC 8364 - 8386 23 54.3 791 bp 
NS5B (1) 
ERN TCGGGCTCCAGGTCACA 8327 - 8343 17 55.1 752 bp 
FF ATGAYACCCGCTGCTTTGACTC 8257 - 8278 22 58.1 FR GRTTGAGTTCGTGTGGAGAGTATCC 9027 - 9051 25 57.9 793 bp NS5B (2) 
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Table 5: Binding prediction results for 7 HLA class I candidate epitopes for HCV-4 vaccine 
design. The dark blue color code of the EpiMatrix Z-sores indicates that the epitope is from 
amongst the top 1% binders of that allele in a random set of peptides, the blue color indicates 
that the epitope is from amongst the top 5% binders, and light blue color code indicates that the 
epitope is from amongst the top 10% binders. Z-scores of the bottom 90% binder peptides are 
not highlighted. The ‘Hits’ column displays the number of HLA alleles each epitope is predicted 
to bind to with a Z-score ≥ 1.64 as a measure of the epitopes’ binding promiscuity. 
Epitope 
Sequence 
Percent 
Conservation 
EpiMatrix Z-Scores 
Hits Location 
A*01:01 A*02:01 A*03:01 A*24:02 B*07:02 B*44:03 
DVVCCSMSY 0.98 2.52 -0.14 2.42 0.19 -0.21 0.6 2 NS5A/NS5B 
RLLAPITAY 0.98 1.86 1.07 2.64 0.09 0.93 2.02 3 NS2/NS3 
FWAKHMWNF 0.96 -0.21 -0.01 -0.54 3.11 1.16 0.97 1 NS4B 
QYLAGLSTL 1 -0.5 0.95 -0.69 2.73 0.55 1.13 1 NS4B 
DPRRRSRNL 0.98 -1.56 -1.12 -1.46 0.45 2.81 -0.49 1 Core 
YLVAYQATV 0.93 0.71 3.2 0.6 0.27 0.56 0.76 1 NS3 
ITYSTYGKF 0.93 1.75 0.37 1.24 1.4 1.49 1.27 1 NS3 
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Table 6: IEDB Results for HLA Class I Binding Assays performed on 4 candidate epitopes for 
HCV-4 vaccine design. The “Quantitative Measure” column displays the quantitative results of 
the HLA binding assays, where: (1) the IC50 results of competition binding assays are displayed in 
nanomolar concentrations (nM), and (2) the results for the HLA dissociation assay are displayed 
in minutes. The “Assay Result” column displays the designated relative binding affinity of the 
epitopes as determined by the authors based on the quantitative results of the assays where 
available, or as determined by the IEDB curators. 
AA Sequence 
Restricting 
Allele 
Assay Description 
Quantitative 
Measure 
Assay Result Ref. 
DVVCCSMSY A26 Purified MHC - Radioactivity Competition  25 nM Positive 101 
            
RLLAPITAY A*03:01 Purified MHC - Radioactivity Competition   4 nM Positive - High 102 
            
YLVAYQATV A*02:01 Purified MHC - Radioactivity Competition   45 nM Positive - High 103 
  
  
45 nM Positive - High 104 
  
  
20 nM Positive - High 105 
  
  
20 nM Positive - High 102 
  
  
20 nM Positive - High 106 
  
  
20.4 nM Positive 107 
  
  
20.4 nM Positive - High 108 
  
  
5 nM Positive - High 109 
  
  
N/A Positive 110 
  
  
59 nM Positive - Intermediate 111 
  
 
Cell bound MHC - Fluorescence Dissociation 1440 min. Positive - High 112 
  
 
Cell bound MHC - Fluorescence Competition 4.8 nM Positive - High 113 
            
  A*02:02 Purified MHC - Radioactivity Competition   39.1 nM Positive - High 108 
  
  
4.3 nM Positive - High 109 
  
  
5.2 nM Positive - High 109 
  
 
Cell bound MHC - Fluorescence Competition 1.5 nM Positive - High 113 
            
  A*02:03 Purified MHC - Radioactivity Competition   15.9 nM Positive - High 108 
  
  
10 nM Positive - High 109 
  
 
Cell bound MHC - Fluorescence Competition 2.1 nM Positive - High 113 
            
  A*02:05 Purified MHC - Radioactivity Competition   4.3 nM Positive - High 109 
  
  
22.6 nM Positive - High 109 
            
  A*02:06 Purified MHC - Radioactivity Competition   82.2 nM Positive - Intermediate 108 
  
  
3.7 nM Positive - High 109 
  
 
Cell bound MHC - Fluorescence Competition 15 nM Positive - High 113 
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Table 6: Continued. 
  A*02:07 Purified MHC - Radioactivity Competition   > 2300 nM Negative 109 
            
  A*68:02 Purified MHC - Radioactivity Competition   33.3 nM Positive - High 108 
  
  
40 nM Positive - High 109 
  
 
Cell bound MHC - Fluorescence Competition 81 nM Positive - Intermediate 113 
            
FWAKHMWNF A*24:02 Cell bound MHC - Fluorescence Association N/A Positive 105 
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Table 7: IEDB Search Results for T-cell Assays performed on 4 candidate epitopes for HCV-4 
vaccine design. “N/A” HCV genotype means that the genotype of the source or infecting virus 
was undetermined. The Method of Restricting Allele Determination column is explained in table 
9. 
AA Sequence 
Restricting 
HLA Allele 
Ref. 
T-cell Assay 
Description 
Assay 
Result 
Source 
HCV 
Genotype 
Patient(s) 
HCV 
Genotype 
Method of 
Restricting  
Allele Determination 
DVVCCSMSY A26 101 ICS (IFN-γ) Positive 1 1 1C 
    
    
  
114 ICS (IFN-γ) Positive 1 1 1B  
 
             
YLVAYQATV A2 108 51Cr Release Cytotoxicity Positive N/A N/A 3C 
    
 
   
  
115 Cytotoxicity Assay Positive 1 N/A 3B  
    
 
   
  
116 Cytotoxicity Assay Positive 1 N/A 3B 
    
 
   
  
117 ELISpot (IFN-γ) Positive 1 N/A 3B 
    
 
   
  
118 ELISpot (IFN-γ) Positive 1 N/A 3A 
    
 
   
 
A*02:01 102 51Cr Release Cytotoxicity Positive N/A N/A 2C   
 
  
111 51Cr Release Cytotoxicity Negative 1 N/A 3C 
    
 
   
  
119 ELISpot (IFN-γ)
 
Negative 1 N/A 3B 
    
 
   
  
120 ELISpot (IFN-γ)
 
Negative 1 N/A 3C 
    
 
   
FWAKHMWNF A*24:02 121 
MHC Tetramer Staining 
ELISpot (IFN-γ) 
Positive 1 1 2A 
    
 
   
  
122 MHC Tetramer Staining Positive N/A N/A 2 
    
 
   
  
105 51Cr Release Cytotoxicity Positive 1 1 3C 
 
             
DPRRRSRNL B7 123 ELISpot (IFN-γ) Positive 1 1 3B  
    
 
   
  
124 51Cr Release Cytotoxicity Positive N/A 1 1B 
    
 
   
  
125 ELISpot (IFN-γ) Positive 1 N/A 3B 
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Table 7: Continued 
  
126 51Cr Release Cytotoxicity Positive N/A N/A 3B 
    
 
   
  
127 ELISpot (IFN-γ) Positive 1 N/A 3B 
    
 
   
  
128 ELISpot (IFN-γ) Negative 1 N/A 3B 
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Table 8: Restricting HLA allele determination. Methods of restricting HLA allele determination 
of T-cell assays listed in table 8.  
Method of Restricting Allele Determination 
1 
T-cell assay performed on CD8+ T-cells from HLA-X+ individuals utilizing different 
APCs with matched and mismatched HLA alleles to demonstrate allelic restriction 
2 
T-cell assay performed on CD8+ T-cells from HLA-X+ individuals utilizing APC or HLA 
tetramers presenting the peptide where the is only a single type of HLA present to 
demonstrate allelic restriction 
3 
T-cell assay performed on CD8+ T-cells from HLA-X+ individuals utilizing APCs that 
are HLA-X+ presenting the test epitope on their surface 
Basis for prediction/knowledge of Restriction 
A In silico binding prediction / Contain HLA binding motif 
B Cited reference 
C In vitro binding assay 
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Table 9: Retrospective validation results of 7 predicted HLA class I epitopes. The Z-scores of 
the supertype alleles whose binding predictions were retrospectively validated are emphasized 
by an underline and in bold red font.  
AA 
Sequence 
EpiMatrix Z-Scores Empirically demonstrated  
HLA restrictions (Supertype) 
Prediction 
Validated? A*01:01 A*02:01 A*03:01 A*24:02 B*07:02 B*44:03 
DVVCCSMSY 2.52 -0.14 2.42 0.19 -0.21 0.6 A26 (A01) Yes 
RLLAPITAY 1.86 1.07 2.64 0.09 0.93 2.02 A*03:01 (A03) Yes 
ITYSTYGKF 1.75 0.37 1.24 1.4 1.49 1.27 A*24:02 (A24) Yes (top 10%) 
YLVAYQATV 0.71 3.2 0.6 0.27 0.56 0.76 A*02:01 (A02) 
Yes 
  
      
A*02:02 (A02) 
  
      
A*02:03 (A02) 
  
      
A*02:05 (A02) 
  
      
A*02:06 (A02) 
              A*68:02 (A02) 
FWAKHMWNF -0.21 -0.01 -0.54 3.11 1.16 0.97 A*24:02 (A24) Yes 
QYLAGLSTL -0.5 0.95 -0.69 2.73 0.55 1.13 A*02:01 (A02) No 
DPRRRSRNL -1.56 -1.12 -1.46 0.45 2.81 -0.49 B7 (B07) Yes 
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Table 10: Five Immunogenic Consensus Sequence peptides constructed by EpiAssembler. The 
9-mer frames of the core of the ICS peptides are emphasized in the ICS sequence column. The 
Open Reading Frame (ORF) coverage column displays the percentage of the HCV-4 sequences 
covered by each ICS peptide with regard to the conservation of its 9-mer core frames, 
collectively, across the sequences analyzed. 
ICS Sequence 
ORF 
Coverage 
EpiMatrix 
Cluster Score 
Janus Matrix 
Cluster Score 
Location Region 
SQGYKVLVLNPSVAATLGFG 1 35.24 14.23 1246 - 1265 NS3 
VSGIQYLAGLSTLPGNPA 1 18.78 4.58 1769 - 1786 NS4B 
STQQTLLFNILGGWVAAQI 1 11.32 2.23 1802 - 1820 NS4B 
EGAVQWMNRLIAFASRGNHVA 1 23.46 19.42 1910 - 1930 NS4B 
PTIWVRMILMTHFFSILQXQE 0.98 24.91 19.03 2837 - 2857 NS5B 
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Table 11: Component 9-mer frames of the ICS peptide NS31246-1265 (SQGYKVLVLNPSVAATLGFG). The table illustrates the Conservatix and 
EpiMatrix scores of each overlapping 9-mer frame in the peptide. Z-score color codes follow the same rules stated in table 6. Epibars (9-mer 
frames that have 4 or more ‘hits’) are highlighted in yellow.  
9-mer 
Frame 
Percent 
Conservation 
EpiMatrix Z-Scores 
Hits 
DRB1*01:01 DRB1*03:01 DRB1*04:01 DRB1*07:01 DRB1*08:01 DRB1*11:01 DRB1*13:01 DRB1*15:01 
SQGYKVLVL 0.02 -0.08 -0.37 0.14 0.89 0.26 -0.08 1.1 0.45 0 
QGYKVLVLN 0.98 -1.14 -0.83 -1.37 -0.81 0.73 -0.66 -0.37 -1.09 0 
GYKVLVLNP 0.98 -0.45 -0.47 0.36 0.15 -0.6 0.24 -0.11 -0.69 0 
YKVLVLNPS 0.98 1.81 1.93 2.02 1.43 2.6 3.08 1.35 2.1 6 
KVLVLNPSV 1 1.59 0.97 1.31 1.33 0.87 1.61 1.26 1.9 1 
VLVLNPSVA 1 1.9 1.39 1.73 1.48 1.31 1.74 1.49 1.58 3 
LVLNPSVAA 1 2.15 2.04 2.28 1.76 1.6 1.59 2 1.77 6 
VLNPSVAAT 1 0.62 0.02 1.15 0.41 0.35 0.64 0.9 0.19 0 
LNPSVAATL 1 1.97 1.83 1.39 1.9 0.82 1.45 1.68 1.38 4 
NPSVAATLG 1 0.22 -0.39 0.08 -0.69 -0.18 -0.65 -0.18 -0.06 0 
PSVAATLGF 1 -0.51 0.19 0.67 0.24 -0.34 -0.29 0.32 -0.25 0 
SVAATLGFG 1 -0.44 0.95 -0.35 -0.68 0.85 0.22 -0.17 1.05 0 
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Table 12: IEDB Search Results for HLA Class II Binding Assays performed on 4 ICS peptides. The 
“Test Sequence” column lists the peptide sequence actually tested by the authors of the listed 
references; AA residues identical to the ICS sequence are colored in black, mismatched residues 
are colored in red and are underlined, AA residues outside the ICS frame are faded in grey. The 
“IC50” column displays the results of the purified MHC competition binding assays in nanomolar 
concentrations (nM). 
ICS Sequence Test Sequence Ref. 
Restricting 
Allele 
IC50 Assay Result 
SQGYKVLVLNPSVAATLGFG GYKVLVLNPSVAAT 132 DRB1*01:01 1.4 Positive -High 
  
133 DRB1*04:01 7.8 Positive -High 
   
DRB1*04:04 33 Positive -High 
   
DRB1*04:05 141 Positive -Int 
   
DRB1*07:01 126 Positive -Int 
   
DRB1*08:02 21 Positive -High 
   
DRB1*09:01 266 Positive -Int 
   
DRB1*11:01 75 Positive -High 
   
DRB1*13:02 3.5 Positive -High 
   
DRB1*15:01 39 Positive -High 
   
DRB1*08:03 1124 Negative 
   
DRB1*12:01 4604 Negative 
   
DRB5*01:01 3695 Negative 
 
GYKVLVLNPSV 134 DRB1*11:01 26 Positive -High 
 
GYKVLVLNPSVAATL 135 DRB1*04:01 N/A Positive 
 
KVLVLNPSVAATLGF 136 DR1 8 Positive -High 
   
DR4 20 Positive -High 
   
DR7 7 Positive -High 
   
DR11 390 Positive 
   
DR15 210 Positive 
   
DRB5 447 Positive 
   
DR3 4183 Negative 
   
DR13 10000 Negative 
   
DRB3 40000 Negative 
   
DRB4 6481 Negative 
 
AQGYKVLVLNPSVAATLGFGAYMSKAHGID 136 DR4 5 Positive -High 
   
DR15 57 Positive -High 
   
DR11 40 Positive -High 
   
DR7 15 Positive -High 
   
DR1 1 Positive -High 
   
DR13 900 Positive -Low 
   
DRB5 1225 Negative 
   
DR3 2500 Negative 
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Table 12: Continued. 
   
DRB3 >100000 Negative 
   
DRB4 2449 Negative 
 
GYKVLVLNPSVAATLGFGAY 137 DRB1*01:01 3.5 Positive -High 
   
DRB1*04:01 9.7 Positive -High 
   
DRB1*07:01 23 Positive -High 
   
DRB1*08:02 80 Positive -High 
   
DRB1*09:01 20 Positive -High 
   
DRB1*11:01 240 Positive -Int 
   
DRB1*13:02 4.1 Positive -High 
   
DRB1*15:01 42 Positive -High 
   
DRB5*01:01 8154 Negative 
EGAVQWMNRLIAFASRGNHVA GEGAVQWMNRLIAFASRGNHV 137 DRB1*01:01 3.2 Positive -High 
   
DRB1*04:01 361 Positive -Int 
   
DRB1*07:01 221 Positive -Int 
   
DRB1*08:02 158 Positive -Int 
   
DRB1*11:01 14 Positive -High 
   
DRB5*01:01 182 Positive -Int 
   
DRB1*09:01 6818 Negative 
 
GPGEGAVQWMNRLIAFASRG 137 DRB1*01:01 8.7 Positive -High 
   
DRB1*11:01 88 Positive -High 
   
DRB1*04:01 5328 Negative 
   
DRB1*07:01 6305 Negative 
 
GAVQWMNRLIAFASRGNHVS 138 DRB1*01:01 13 Positive -High 
   
DRB1*04:01 698 Positive -Int 
   
DRB1*04:04 35.9 Positive -High 
   
DRB1*15:01 3.03 Positive -High 
   
DRB1*03:01 92.5 Positive -High 
VSGIQYLAGLSTLPGNPA NFISGIQYLAGLSTLPGNPA 137 DRB1*01:01 10 Positive -High 
   
DRB1*04:01 84 Positive -High 
   
DRB1*08:02 70 Positive -High 
   
DRB1*09:01 441 Positive -Int 
   
DRB1*11:01 74 Positive -High 
   
DRB5*01:01 606 Negative 
   
DRB1*07:01 >10000 Negative 
 
QYLAGLSTLPGNGN 138 DRB1*01:01 2.9 Positive -High 
   
DRB1*04:01 3 Positive -High 
   
DRB1*15:01 99.2 Positive -High 
   
DRB1*04:04 1.97 Positive -High 
   
DRB1*03:01 >70000 Negative 
 
GIQYLAGLSTLPGNPAIASL 135 DRB1*04:01 N/A Positive 
  
138 DRB1*04:01 13.2 Positive -High 
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Table 12: Continued. 
   
DRB5*01:01 357 Positive -Int 
   
DRB1*15:01 365 Positive -Int 
   
DRB1*11:01 5.31 Positive -High 
   
DRB1*04:05 6.28 Positive -High 
   
DRB1*13:02 214 Positive -Int 
   
DRB1*01:01 0.946 Positive -High 
   
DRB1*07:01 2180 Negative 
   
DRB1*03:01 35000 Negative 
  
139 DRB1*01:01 1 Positive -High 
   
DRB1*04:01 13 Positive -High 
   
DRB1*04:05 6 Positive -High 
   
DRB1*11:01 5 Positive -High 
   
DRB1*13:02 214 Positive -Int 
   
DRB1*15:01 378 Positive -Int 
   
DRB5*01:01 357 Positive -Int 
   
DRB1*03:01 >69767 Negative 
   
DRB1*07:01 2176 Negative 
STQQTLLFNILGGWVAAQI LTTSQTLLFNILGGWVAAQL 138 DRB1*15:01 17.4 Positive -High 
  
  
DRB1*07:01 638 Positive -Int 
  
  
DRB1*04:05 502 Positive -Int 
  
  
DRB1*13:02 101 Positive -Int 
  
  
DRB1*01:01 2.5 Positive -High 
  
  
DRB1*04:01 2470 Negative 
  
  
DRB5*01:01 1950 Negative 
  
  
DRB1*11:01 12300 Negative 
      DRB1*03:01 3920 Negative 
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Table 13: IEDB Search Results for CD4+ T-cell Assays performed on 3 ICS peptides. The “Test/Optimal  Sequences” column lists the peptide 
sequences actually tested by the authors or the optimal sequence within the tested peptides responsible for the maximal T-cell response 
(denoted by an asterix*) as shown by truncation analysis. Methods of restricting allele determination follow the same rules of table 9.  
ICS Sequence Ref. Assay Test/Optimal Sequences 
Source 
Genotype 
Subjects 
Genotype 
Restricting Allele 
Method of Restricting 
Allele Determination 
SQGYKVLVLNPSVAATLGFG 141 
3
H -thymidine cell proliferation QGYKVLVLNPSVAATLGFGA N/A N/A DRB1*11:01 1B 
  MHC Tetramer staining GYKVLVLNPSVAAT N/A N/A DRB1*11:01 2B 
 135 MHC Tetramer staining GYKVLVLNPSVAATL N/A N/A DRB1*04:01 2B 
 132 
3H -thymidine cell proliferation GYKVLVLNPSVAAT 1,2 1, N/A DRB1*12:01 1C 
      DRB1*11:01  
      DRB1*13:02  
      DRB1*04:01  
      DRB1*16:01  
 141 MHC Tetramer staining GYKVLVLNPSVAATL N/A N/A DR4 2B 
 142 
3H -thymidine cell proliferation VLVLNPSVAATLGFGAYM N/A N/A DRB1*04:01 2 
  Cytokine Release (IL-2)      
VSGIQYLAGLSTLPGNPA 144 3H -thymidine cell proliferation QYLAGLSTLPGN* N/A 3 DRB1*11:04 1 
   MWNFISGIQYLAGLSTLPGN 1 3 DRB1*11:01  
 139 ICS (IFN-γ) LAGLSTLPGNP* 1 1 DRB1*04:01 1C 
      DRB1*11:04  
      DRB1*04:07  
      DRB1*04:04  
 141 MHC Tetramer staining SGIQYLAGLSTLPGNPAIASL N/A N/A DR4 2B 
  Cytotoxicity Assay 
 
     
 135 MHC Tetramer staining SGIQYLAGLSTLPGNPAIASL N/A N/A DRB1*04:01 2C 
STQQTLLFNILGGWVAAQI 144 
3
H–thymidine cell proliferation LFNILGGWVA* N/A 1,3 DRB1*01:01 1 
   FNILGGWVAAQL N/A 1,3 DRB1*01:01  
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Table 14: Retrospective validation results of ICS peptide NS31246-1265 (SQGYKVLVLNPSVAATLGFG). 
True positive (TP) and false positive (FP) assignments validate or refute the EpiMatrix binding 
predictions outlined in table 12. Cells without assignments lack corresponding empirical data for 
comparison.   
Type  
of Assay 
Validation Results 
DRB1*01:01 DRB1*03:01 DRB1*04:01 DRB1*07:01 DRB1*08:01 DRB1*11:01 DRB1*13:01 DRB1*15:01 
HLA Binding 
 Assay 
TP --- TP TP TP TP TP TP 
--- --- --- --- --- TP --- --- 
--- --- TP --- --- --- --- --- 
TP FP TP TP --- TP --- TP 
TP --- TP TP TP TP TP TP 
CD4+ T-cell  
Assay 
--- --- --- --- --- TP --- --- 
--- --- TP --- --- --- --- --- 
--- --- TP --- --- TP TP --- 
--- --- TP --- --- --- --- --- 
Overall  
Results 
TP FP TP TP TP TP TP TP 
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Table 15: HLA Class II binding assay results.  The binding affinity scale is divided as follows: (1) 
Strong Binder: IC50 < 10,000 nM, (2) Moderate Binder: 10,000 < IC50 <100,000 nM, (3) Weak 
binder: IC50 > 100,000 nM. 
ICS Sequence 
DRB1*01:01 DRB1*04:01 DRB1*07:01 DRB1*15:01 
Highest 
Z-Score 
IC50 (nM) 
Highest 
Z-Score 
IC50 (nM) 
Highest 
Z-Score 
IC50 (nM) 
Highest 
Z-Score 
IC50 (nM) 
SQGYKVLVLNPSVAATLGFG 2.15 44 2.28 123 1.9 3,010 2.1 711 
VSGIQYLAGLSTLPGNPA 2.54 148 2.25 694 1.93 Non-binder 2.25 1,239 
STQQTLLFNILGGWVAAQI 2.33 215 1.94 721 1.77 122,087 1.6 782 
EGAVQWMNRLIAFASRGNHVA 2.54 2,726 1.52 20,416 1.55 44,713 2.56 103 
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Table 16: Amplified and Sequenced HCV Samples from the Egyptian Population. “Amp” means 
that the region of the corresponding sample was successfully amplified by RT-PCR and Nested 
PCR. “Seq” means that the region was successfully sequenced in the forward and/or reverse 
directions. 
Sample Core NS3 (1) NS3 (2) NS4B NS5B (1) NS5B (2) 
K1 --- --- Amp + Seq --- --- --- 
K2 --- Amp + Seq Amp + Seq Amp + Seq Amp + Seq --- 
K3 --- --- Amp + Seq --- --- --- 
K4 --- Amp + Seq Amp + Seq Amp + Seq --- --- 
K5 --- --- Amp + Seq Amp + Seq --- --- 
K6 --- Amp + Seq --- --- --- --- 
K7 --- Amp + Seq --- --- --- --- 
K8 --- --- --- --- Amp + Seq --- 
K9 --- --- --- --- Amp Only --- 
K10 --- Amp + Seq Amp Only --- --- --- 
K11 Amp + Seq --- --- --- --- --- 
K12 Amp + Seq --- --- Amp + Seq --- --- 
K13 Amp + Seq --- --- Amp + Seq Amp + Seq --- 
K14 Amp + Seq --- --- --- --- --- 
K15 --- --- --- --- Amp + Seq --- 
 
 
 
 
 
 
 
 
 
 
93 
 
Table 17: Egyptian population successfully sequenced sample regions’ sizes, chromatogram qualities, and locations on the HCV polyprotein 
sequence. The letters “F” and “R” in the sample region column label the forward and reverse sequences obtained from the sequencing 
reactions. The translation reading frames of the sequences were determined using the BLASTX analysis. The locations of the translated amino 
acid sequences on the reference HCV-1a (H77) AA sequence were determined using the Sequence Locator tool of the HCV Los Alamos database.  
Sample 
Sample 
Region 
Chromatogram Quality 
Length after 
Truncation (nt) 
Reading 
Frame 
Location on HCV polyprotein (AA) 
K1 
NS3(2)-F High 741 +1/+3 1354 – 1486 / 1497 - 1599 
NS3(2)-R Low --- --- --- 
K2 
NS3(1)-F High 633 +1 1152 - 1362 
NS3(1)-R High 616 -1 1111 - 1315 
NS3(2)-F High 680 +1 1358-1578 
NS3(2)-R High 738 -2 1352 - 1596 
NS4B-F Low --- --- --- 
NS4B-R High 568 -3 1717 - 1904 
NS5B(1)-F High 651 +3 2447 - 2662 
NS5B(1)-R --- --- --- --- 
K3 
NS3(2)-F High 751 +1 1354 - 1603 
NS3(2)-R High 781 -1 1337 - 1596 
K4 
NS3(1)-F High 632 +3 1151 - 1359 
NS3(1)-R Low --- --- --- 
NS3(2)-F Low --- --- --- 
NS3(2)-R High 570 -1 1354 - 1543 
NS4B-F High 693 +2 1724 - 1952 
NS4B-R High 659 -2 1717 - 1935 
K5 
NS3(2)-F High 766 +1 1349 - 1603 
NS3(2)-R High 781 -1 1337 - 1596 
NS4B-F High 678 +2 1730 - 1954 
NS4B-R High 674 -1 1709 - 1927 
K6 
NS3(1)-F Low --- --- --- 
NS3(1)-R High 443 N/A N/A 
K7 
NS3(1)-F High 464 N/A N/A 
NS3(1)-R High 541 N/A N/A 
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Table 17: Continued. 
K8 
NS5B(1)-F Low --- --- --- 
NS5B(1)-R High 407 N/A N/A 
K10 
NS3(2)-F High 478 N/A N/A 
NS3(2)-R High 487 N/A N/A 
K11 
Core-F Low --- --- --- 
Core-R High 392 -1 1 - 117 
K12 
Core-F High 503 +3 14 - 180 
Core-R High 503 -2 1 - 155 
NS4B-F High 695 +1 1746 – 1952 
NS4B-R High 704 -3 1710 - 1943 
K13 
Core-F High 504 +1 14 -180 
Core-R High 505 -1 1 – 155 
NS4B-F High 619 +1 1739 - 1944 
NS4B-R High  688 -3 1708 - 1924 
NS5B(1)-F High 650 +3 2450 – 2664 
NS5B(1)-R High 652 -1 2422 – 2637 
K14 
Core-F High 469 +3 25 - 179 
Core-R High 502 -2 1 - 155 
K15 
NS5B(1)-F High  676 +2 2443 – 2665 
NS5B(1)-R High 679 -3 2426 - 2650 
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Table 18: Consensus assembled HCV sequences and their locations. 
Sample Region Location (AA) 
K1 NS3(2) 
1354 – 1486 
1497 - 1599 
K2 
NS3 1111 - 1596 
NS4B 1717 - 1904 
NS5B(1) 2447 - 2662 
K3 NS3(2) 1337 - 1603 
K4 
NS3 1151 - 1543 
NS4B 1717 - 1952 
K5 
NS3(2) 1337 - 1603 
NS4B 1709 - 1954 
K11 Core 1 - 117 
K12 
Core 1 - 180 
NS4B 1710 - 1952 
K13 
Core 1 - 180 
NS4B 1708 - 1944 
NS5B(1) 2422 - 2664 
K14 Core 1 - 179 
K15 NS5B(1) 2426 - 2665 
 
 
 
 
 
 
 
 
 
 
96 
 
Table 19: Example of the conservation analysis results across the newly partially re-sequenced 
HCV genomes from the Egyptian population. The “Sequence Coverage” column displays the 
number of sequences in which the epitopes were conserved as part of the total number of new 
sequences that cover their locations. 
Epitope Sequence 
Location 
(AA) 
Region 
Sequence 
Coverage 
% Conservation 
HLA Class I Epitopes 
YLVAYQATV 1585 - 1593 NS3 4/4 100% 
ITYSTYGKF 1291 - 1299 NS3 1/2 50% 
FWAKHMWNF 1760 -1768 NS4B 5/5 100% 
RPMDVKFPG 18 - 26 Core 3/4 75% 
HLA Class II ICS Peptides 
SQGYKVLVLNPSVAATLGFG 1246 - 1265 NS3 2/2 100% 
VSGIQYLAGLSTLPGNPA 1769 - 1786 NS4B 5/5 100% 
STQQTLLFNILGGWVAAQI 1802 - 1820 NS4B 5/5 100% 
EGAVQWMNRLIAFASRGNHVA 1910 - 1930 NS4B 4/4 100% 
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9. FIGURES 
 
 
Figure 1: HCV Entry into Hepatocytes. Schematic representation of our current understanding 
of the viral entry step in the HCV life cycle.  Reprinted by permission from Macmillan Publishers 
Ltd: Nature Reviews Microbiology [12], copyright 2007. 
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Figure 2: HCV RNA and Polyprotein. Schematic representation of the HCV RNA genome, the 
precursor polyprotein molecule, and its processing into the structural and non-structural 
proteins of HCV. Reprinted from [12]. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Microbiology [12], copyright 2007. 
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Figure 3: HCV Proteins. Schematic representation of the structures of the HCV proteins and 
their ER membrane associations. Reprinted from [12]. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Microbiology [12], copyright 2007. 
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Figure 4: Type I and III IFN production. Detailed schematic depiction of how HCV induces the 
production of type I and III IFNs by triggering intracellular signaling pathways that lead to their 
expression. Reprinted with permission from [29]. 
 
 
101 
 
 
Figure 5: Maturation of Dendritic Cells. Schematic representation of the uptake of HCV antigens 
by immature dendritic cells (iDCs), and their subsequent maturation into myeloid dendritic cells 
(mDCs); which in turn activate naïve T-cells in the lymphoid organs. Reprinted from [40] with 
permission from Elservier. 
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Figure 6: The Evolution of the T-cell response to HCV. Graphical illustration of the changes in 
viral and T-cell titers across the 3 phases of the T-cell response to HCV; and the possible 
outcomes of infection: a) weak, short-lasting T-cell response ending in viral persistence, b) 
initially strong T-cell response that is not sustained, ending in viral persistence, and c) Strong and 
sustained T-cell response ending in viral clearance. Reprinted with permission from [43]. 
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Figure 7: Inhibition of IFN production and ISG protein action. Schematic representation of the 
interference of different HCV proteins with the expression of type I IFNs and ISG and with the 
actions of the ISG protein products; the interference of HCV proteins is emphasized in red. 
Reprinted with permission from [14]. 
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Figure 8: Suppressive actions of T-regulatory lymphocytes. Schematic illustration of the 
mechanisms by which Tregs suppress the immune response: a) via inhibitory cytokines, b) 
triggering apoptosis, c) metabolic disruption, and d) inhibition of DC maturation. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews Immunology [51], copyright 2008. 
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Figure 9: HCV evasion of neutralizing antibodies. Schematic illustration of how HCV evades 
recognition and capture by neutralizing antibodies. Reprinted with permission from [15]. 
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Figure 10: The interaction between HCV and the host immune system. A schematic illustration 
of the immune response to HCV in the acute phase of the infection, and the mechanisms by 
which HCV evades that response to lead the infection to progress to the chronic phase. 
Reprinted with permission from [17]. 
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Figure 11: The HLA class II binding groove. A 3-dimentional model of the binding groove of an 
HLA class II molecule bound to an epitope. The side chains of the amino acid residues P1, 4, 6, 
and 9 are anchored in the pockets of the binding clefts. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Immunology [67], copyright 2006. 
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Figure 12: The EpiMatrix frequency matrix for the Class I HLA allele A*02:01. The colors in the 
grid represents the frequency that a given amino acid residue is observed at a specific amino 
acid position in a large set of natural HLA-A*02:01 epitopes. The color “Red” indicates the amino 
acid is frequently present at that position, and therefore promotes epitope binding to the HLA 
molecule when present. “Blue” indicates the opposite. Reprinted with permission from [62]. 
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Figure 13: Construction of an Immunogenic Consensus Sequence peptide by EpiAssembler. 
First, EpiAssembler identifies the most highly conserved epitope across the analyzed sequences 
and the one that is most promiscuously immunogenic, which here is SIVNRVRQG (an X denotes a 
mismatch with the conserved peptide), the program then identifies overlapping highly 
conserved and promiscuously immunogenic peptides, and then assembles those peptides into 
an extended ICS. Reprinted with permission from [23]. 
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Figure 14: The two faces of the T-cell epitope. A 3D model of a T-cell epitope in association with 
an HLA molecule and a T-cell receptor, with the ‘epitope’ residues facing the TCR, and the 
‘agretope’ residues facing the HLA molecule. Reprinted with permission from [84]. 
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Figure 15: Primer Alignment. An example of the alignment of the primer AF with the 46 HCV-4 
sequences using the ClustalX 2.1 software. 
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Figure 16: HCV RNA amplification results. Examples of electrophoresis gel photos presenting 
the results of the nested PCR amplification reactions for 11 sample regions are displayed. The 
results were analyzed on a 1% agarose gel, with 5 μL of a 100 bp DNA Ladder (Promega, WI, 
USA) loaded into the first well of each gel, and  5 μL of each of the sample regions amplicons 
added to the other wells; all mixed with 2 μL loading dye. The gel was then run at 95V for 1 hour 
in 1X TBE running buffer, and the amplicon bands were visualized on an ECX-20.M 
transilluminator (Vilber Lourmat, Marne-la-Vallée, France). Images of the gels were taken using 
a Samsung S2 8.0 megapixel mobile phone camera (Samsung, Seoul, South Korea). 
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Figure 17: Sequencing Chromatograms Qualities. An example of a high quality sequencing 
chromatogram is illustrated at the top (part of the sequencing chromatogram of sample region 
K2-NS3(1)-F) with sharp peaks and low background noise. An example of a low quality 
chromatogram is illustrated at the bottom (part of the sequencing chromatogram of sample 
region K2-NS4B-F) with high background noise. 
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Figure 18:  Flowchart summarizing the performed in silico T-cell epitope prediction and 
retrospective validation process. 
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